<SEC-DOCUMENT>0000947871-23-001022.txt : 20231031
<SEC-HEADER>0000947871-23-001022.hdr.sgml : 20231031
<ACCEPTANCE-DATETIME>20231031163408
ACCESSION NUMBER:		0000947871-23-001022
CONFORMED SUBMISSION TYPE:	424B2
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20231031
DATE AS OF CHANGE:		20231031

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			QUEST DIAGNOSTICS INC
		CENTRAL INDEX KEY:			0001022079
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-MEDICAL LABORATORIES [8071]
		IRS NUMBER:				161387862
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B2
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-266315
		FILM NUMBER:		231365170

	BUSINESS ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094
		BUSINESS PHONE:		9735202700

	MAIL ADDRESS:	
		STREET 1:		500 PLAZA DRIVE
		CITY:			SECAUCUS
		STATE:			NJ
		ZIP:			07094

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORNING CLINICAL LABORATORIES INC
		DATE OF NAME CHANGE:	19960903
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B2
<SEQUENCE>1
<FILENAME>ss2656398_424b2.htm
<DESCRIPTION>PROSPECTUS SUPPLEMENT
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: right"><B>Filed Pursuant to Rule 424(b)(2)<BR>
Registration No. 333-266315</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B><U>PROSPECTUS SUPPLEMENT<BR>
</U></B>(To prospectus dated July 25, 2022)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-size: 18pt">$750,000,000</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><IMG SRC="image_001.jpg" ALT="Description: C:\Users\dy23967\Desktop\Quest-logo[2].jpg" STYLE="height: 115px; width: 241px"></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">Quest Diagnostics Incorporated<BR>
$750,000,000 &nbsp;6.400% Senior Notes due 2033</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We are offering $750,000,000 aggregate
principal amount of 6.400% senior notes due 2033&nbsp;(the &ldquo;notes&rdquo;). The notes will mature on November 30, 2033. We will
pay interest on the notes semiannually on May 30 and November 30 of each year, beginning &nbsp;May 30, 2024. We may redeem some or
all of the notes at any time at the applicable redemption prices described in this prospectus supplement.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes will be senior unsecured obligations
of ours and will rank equally with our other existing and future senior unsecured obligations. The notes will be issued only in registered
form in minimum denominations of $2,000 and integral multiples of $1,000 in excess thereof.</P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><B>Investing in the notes involves risks that
are described in the &ldquo;Risk Factors&rdquo; section of our Annual Report on Form 10-K for the year ended December 31, 2022, as they
may be amended, updated or modified in our reports filed with the Securities and Exchange Commission, which are incorporated by reference
into this prospectus supplement, and in the &ldquo;Risk Factors&rdquo; section beginning on page <A HREF="#a_002">S-6</A> of this prospectus supplement.</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 64%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 21%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid"><B>Per Note</B></P></TD>
    <TD STYLE="width: 15%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid"><B>Total</B></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 8pt">Public offering price<SUP>(1)</SUP></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 8pt">99.947%</FONT></TD>
    <TD STYLE="text-align: right; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 8pt">$749,602,500</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 8pt">Underwriting discount </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 8pt">0.650%</FONT></TD>
    <TD STYLE="text-align: right; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 8pt">&nbsp;&nbsp;&nbsp;&nbsp;$4,875,000</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 8pt">Proceeds, before expenses, to us </FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: right"><FONT STYLE="font-size: 8pt">99.297%</FONT></TD>
    <TD STYLE="text-align: right; padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 8pt">$744,727,500</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 6pt; text-indent: 0.75pt"><FONT STYLE="font-size: 8pt"><SUP>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT></SUP><FONT STYLE="font-size: 7pt">Plus
accrued interest from November 1, 2023, if settlement occurs after that date.</FONT></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><B>Neither the Securities and Exchange Commission
nor any state securities commission has approved or disapproved of these securities or determined if this prospectus supplement or the
accompanying prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><B>We do not intend to apply for listing of the
notes on any securities exchange. Currently, there is no public trading market for the notes.</B></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 1pt; text-indent: 0.5in">The notes will be ready for delivery in book-entry
form only through the facilities of The Depository Trust Company for the accounts of its participants, including Euroclear Bank S.A./N.V.,
as operator of the Euroclear System, and Clearstream Banking, <I>soci&eacute;t&eacute; anonyme</I>, on or about November 1,
2023.</P>
<!-- Field: Rule-Page --><DIV STYLE="margin: 6pt auto; width: 35%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><I>Joint Book-Running Managers</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 34%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Goldman Sachs &amp; Co. LLC</B></FONT></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Mizuho </B></FONT></TD>
    <TD STYLE="width: 33%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Morgan Stanley</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>J.P. Morgan</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>&nbsp;</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Wells Fargo Securities</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><I>&nbsp;</I></P>

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><I>Co-Managers</I></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Credit Agricole CIB</B></FONT></TD>
    <TD STYLE="width: 24%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>MUFG</B></FONT></TD>
    <TD STYLE="width: 22%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>PNC Capital Markets LLC</B></FONT></TD>
    <TD STYLE="width: 30%; padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>Fifth Third Securities</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>KeyBanc Capital Markets</B></FONT></TD>
    <TD COLSPAN="2" STYLE="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><FONT STYLE="font-size: 8pt"><B>BofA Securities</B></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt"><FONT STYLE="font-size: 8pt"><B>BNY Mellon Capital Markets, LLC</B></FONT></TD></TR>
  </TABLE>
<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif">&nbsp;</P>

<!-- Field: Rule-Page --><DIV STYLE="margin: 3pt auto; margin-bottom: 6pt; width: 35%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 8pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">The date of this prospectus supplement is
October 30, 2023</P>




<!-- Field: Page; Sequence: 1; Options: NewSection -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0pt">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Table of Contents</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: right"><B>Page</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Prospectus Supplement</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 1.75pt; width: 91%"><A HREF="#a_001">SUMMARY</A></TD>
    <TD STYLE="padding: 1.75pt; width: 9%; text-align: right">S-3</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 1.75pt"><A HREF="#a_002">RISK FACTORS</A></TD>
    <TD STYLE="padding: 1.75pt; text-align: right">S-6</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 1.75pt"><A HREF="#a_003">CAUTIONARY STATEMENT FOR PURPOSES OF THE &ldquo;SAFE HARBOR&rdquo; PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995</A></TD>
    <TD STYLE="padding: 1.75pt; text-align: right">S-8</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 1.75pt"><A HREF="#a_004">USE OF PROCEEDS</A></TD>
    <TD STYLE="padding: 1.75pt; text-align: right">S-11</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 1.75pt"><A HREF="#a_005">CAPITALIZATION</A></TD>
    <TD STYLE="padding: 1.75pt; text-align: right">S-12</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 1.75pt"><A HREF="#a_006">DESCRIPTION OF NOTES</A></TD>
    <TD STYLE="padding: 1.75pt; text-align: right">S-13</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 1.75pt"><A HREF="#a_007">UNITED STATES FEDERAL INCOME TAX CONSIDERATIONS</A></TD>
    <TD STYLE="padding: 1.75pt; text-align: right">S-31</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 1.75pt"><A HREF="#a_008">UNDERWRITING (CONFLICTS OF INTEREST)</A></TD>
    <TD STYLE="padding: 1.75pt; text-align: right">S-35</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 1.75pt"><A HREF="#a_009">LEGAL MATTERS</A></TD>
    <TD STYLE="padding: 1.75pt; text-align: right">S-39</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding: 1.75pt"><A HREF="#a_010">EXPERTS</A></TD>
    <TD STYLE="padding: 1.75pt; text-align: right">S-39</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding: 1.75pt"><A HREF="#a_011">WHERE YOU CAN FIND MORE INFORMATION</A></TD>
    <TD STYLE="padding: 1.75pt; text-align: right">S-39</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center"><B>Prospectus</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt; width: 91%"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a1">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt; width: 9%"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a2">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a3">CAUTIONARY STATEMENT FOR PURPOSES OF THE &#8220;SAFE HARBOR&#8221; PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">iii</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a4">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a5">RISK FACTORS</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a6">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a7">SECURITIES WE MAY ISSUE</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a8">DESCRIPTION OF SENIOR DEBT SECURITIES</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a9">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a10">VALIDITY OF THE SECURITIES</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
<TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a11">EXPERTS</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Neither we nor the underwriters have authorized
anyone to provide you with any information or to make any representation not contained in or incorporated by reference into this prospectus
supplement or the accompanying prospectus or included in any free writing prospectus that we may file with the Securities and Exchange
Commission (the &ldquo;SEC&rdquo;) in connection with this offering. Neither we nor the underwriters take any responsibility for, or can
provide any assurances as to, the reliability of any information that others may provide you. Neither we nor the underwriters are making
an offer to sell these securities in any jurisdiction where the offer or sale is not permitted. You should assume that the information
appearing in this prospectus supplement, the accompanying prospectus and the documents incorporated by reference is accurate only as of
their respective dates. Our business, financial condition, cash flows, results of operations and prospects may have changed since these
dates.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0.5in"><B>ABOUT THIS PROSPECTUS
SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">This document has two parts. The first part
consists of this prospectus supplement, which describes the specific terms of this offering and the notes offered. The second part, the
accompanying prospectus, provides more general information, some of which may not apply to this offering. If the description of the offering
varies between this prospectus supplement and the accompanying prospectus, you should rely on the information in this prospectus supplement.&nbsp;</P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Before purchasing any notes, you should carefully
read both this prospectus supplement and the accompanying prospectus, together with the additional information described under the heading
&ldquo;Where You Can Find More Information&rdquo; in this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">References to &ldquo;we,&rdquo; &ldquo;us,&rdquo;
&ldquo;our,&rdquo; &ldquo;Quest Diagnostics&rdquo; and the &ldquo;Company&rdquo; are to Quest Diagnostics Incorporated and its consolidated
subsidiaries or, in the sections entitled &ldquo;Description of Notes&rdquo; and &ldquo;Underwriting (Conflicts of Interest)&rdquo; and
as the context may require, Quest Diagnostics Incorporated only.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 100%; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; padding-top: 12pt; padding-bottom: 12pt; padding-left: 0.25in; text-align: center; text-indent: -0.25in"><B><A NAME="a_001" TITLE="summary"></A>SUMMARY</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt"><I>This summary highlights selected information appearing elsewhere in this prospectus supplement and the documents incorporated herein and may not contain all of the information that is important to you.&nbsp;&nbsp;You should carefully read this prospectus supplement and the accompanying prospectus in their entirety, including the documents incorporated by reference.</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Our Company</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Quest Diagnostics empowers people to take action to improve health
    outcomes. We use our extensive database of clinical lab results to derive diagnostic insights that reveal new avenues to identify and
    treat disease, inspire healthy behaviors and improve healthcare management. Our diagnostic information services business (&ldquo;DIS&rdquo;)
    provides information and insights based on an industry-leading menu of routine, non-routine and advanced clinical testing and anatomic
    pathology testing, and other diagnostic information services. We provide services to a broad range of customers, including patients, clinicians,
    hospitals, independent delivery networks (&ldquo;IDNs&rdquo;), health plans, employers, consumers, and accountable care organizations.
    We offer the broadest access in the United States to diagnostic information services through our nationwide network of laboratories, patient
    service centers and phlebotomists in physician offices and our connectivity resources, including call centers and mobile paramedics, nurses
    and other health and wellness professionals. We are the world&rsquo;s leading provider of diagnostic information services. We provide
    interpretive consultation with one of the largest medical and scientific staffs in the industry. Our DIS business accounted for greater
    than 95% of our consolidated net revenues in 2022.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">In our Diagnostic Solutions (&ldquo;DS&rdquo;) businesses, which
    represent the balance of our consolidated net revenues, we offer a variety of solutions for life insurers and healthcare organizations
    and clinicians. We are the leading provider of risk assessment services for the life insurance industry. In addition, we offer healthcare
    organizations and clinicians robust information technology solutions.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">The patients we serve comprise approximately one-third of the adult
    population of the United States annually, and approximately one-half of the adult population in the United States over a three-year period.
    We estimate that annually we serve approximately half of the physicians and half of the hospitals in the United States.</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">During 2022, we generated net revenues of $9.9 billion and processed approximately 208 million test requisitions through our extensive laboratory network.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt">Our principal executive offices are located at 500 Plaza Drive, Secaucus, New Jersey 07094, telephone number:&nbsp;&nbsp;(973) 520-2700.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="margin-top: 0; margin-bottom: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="padding: 12pt 5.4pt; border-top: Black 1pt solid; border-right: Black 1pt solid; border-left: Black 1pt solid; text-align: center"><B>The Offering</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD COLSPAN="2" STYLE="border-right: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 12pt; padding-left: 5.4pt; text-indent: 0.5in">The following is a brief summary of some of the terms of this offering.&nbsp;&nbsp;For a more complete description of the terms of the notes, see &ldquo;Description of Notes&rdquo; in this prospectus supplement and &ldquo;Description of Senior Debt Securities&rdquo; in the accompanying prospectus.&nbsp;&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 20%; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Issuer</B></TD>
    <TD STYLE="width: 80%; border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">Quest Diagnostics Incorporated.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Notes Offered</B></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">$750,000,000 aggregate
    principal amount of&nbsp;6.400% senior notes due 2033.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Maturity</B></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">November 30,
2033.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="white-space: nowrap; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Interest Payment Dates</B></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">May 30 and
    November 30, beginning May 30, 2024.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Ranking</B></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The notes will be senior unsecured obligations of Quest Diagnostics
    and will rank equally with Quest Diagnostics&rsquo; other existing and future senior unsecured obligations. The notes will be effectively
    subordinated to any existing and future secured obligations of Quest Diagnostics as to the assets securing such obligations.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In addition, the notes will be structurally subordinated to any
    existing and future indebtedness and other obligations of Quest Diagnostics&rsquo; subsidiaries. Quest Diagnostics&rsquo; subsidiaries
    are not guarantors of the notes. To the extent the indenture governing Quest Diagnostics&rsquo; existing debt securities requires any
    domestic subsidiary of Quest Diagnostics to guarantee Quest Diagnostics&rsquo; existing debt securities issued under the indenture, any
    such subsidiary will be required to guarantee the notes in a substantially consistent manner for so long as such subsidiary guarantees
    such existing debt securities.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">As of September 30, 2023, after giving effect to this offering (as
    if the foregoing had occurred on that date), Quest Diagnostics would have had debt outstanding of $4,993
    million, of which $286 million is secured indebtedness of our subsidiaries. As of September 30, 2023, $278 million of the secured indebtedness
    consisted of borrowings outstanding under our secured receivables credit facility.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">For more information, see &ldquo;Description of Notes&rdquo; &ldquo;Use
    of Proceeds&rdquo; and &ldquo;Capitalization.&rdquo;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Optional Redemption</B></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">Prior to August 30,
2033 (three months prior to their maturity
    date) (the &ldquo;Par Call Date&rdquo;), we may redeem the notes at our option, in whole or in part, at any time and from time to time,
    at a redemption price (expressed as a percentage of principal amount and rounded to three decimal places) equal to the greater of:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">(1) (a) the sum of the present values of the remaining
    scheduled payments of principal and interest thereon discounted to the redemption date (assuming the notes matured on the Par Call
    Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined in this
    prospectus supplement) plus 25 basis points less (b) accrued and unpaid interest thereon to the redemption date, and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">(2) 100% of the principal amount of the notes to be redeemed,</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">plus, in either case, accrued and unpaid interest thereon to the
    redemption date.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">On or after the Par Call Date, we may redeem the notes, in whole
    or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the notes being redeemed
    plus accrued and unpaid interest thereon to the redemption date.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">For a more detailed description, see &ldquo;Description of Notes&mdash;Optional
    Redemption.&rdquo;</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 15%; border-top: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Repurchase Upon a Change of Control</B></TD>
    <TD STYLE="width: 85%; border-top: Black 1pt solid; border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">Upon the occurrence of a Change of Control Triggering Event (as defined in this prospectus supplement), we will be required to make an offer to purchase the notes at a price equal to 101% of their principal amount plus accrued and unpaid interest to the repurchase date.&nbsp;&nbsp;See &ldquo;Description of Notes&mdash;Change of Control.&rdquo;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Covenants</B></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">The indenture governing the notes will contain covenants that, among
    other things, will limit our ability and/or the ability of certain of our subsidiaries to:</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;create
    certain liens;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;enter
    into certain sale and leaseback transactions;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;consolidate,
    merge or transfer all or substantially all of our assets; and</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-indent: -0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT>&nbsp;&nbsp;&nbsp;&nbsp;incur
    indebtedness at non-guarantor subsidiaries.</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">These covenants are subject to important exceptions and qualifications,
    which are described in this prospectus supplement. For a more detailed description, see &ldquo;Description of Notes.&rdquo;</P></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Use of Proceeds</B></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">We estimate that the net proceeds from this offering of notes after deducting underwriting discounts but before deducting other expenses of the offering will be approximately $744,727,500.&nbsp;&nbsp;We expect to use the net proceeds from this offering for general corporate purposes, which may include the redemption or repayment of indebtedness.&nbsp;&nbsp;The indebtedness we may redeem or repay with the net proceeds of this offering includes our $300 million aggregate principal amount of 4.25% Senior Notes due 2024 (the &ldquo;4.25% Senior Notes&rdquo;) and any outstanding borrowings under our senior unsecured revolving credit facility and our secured receivables credit facility. See &ldquo;Use of Proceeds.&rdquo; This prospectus supplement is not a notice of redemption.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Conflicts of Interest</B></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">As described in &ldquo;Use of Proceeds,&rdquo; the net proceeds of this offering may be used for general corporate purposes, which may include the redemption or repayment of indebtedness, including our 4.25% Senior Notes pursuant to the applicable provisions of the indenture governing these notes and any outstanding borrowings under our senior unsecured revolving credit facility and our secured receivables credit facility.&nbsp;&nbsp;Certain of the underwriters (or their affiliates) may hold and would receive a portion of the proceeds from this offering if such notes were to be redeemed or repaid.&nbsp;&nbsp;In addition, certain of the underwriters (or their affiliates) may be lenders under our senior unsecured revolving credit facility or our secured receivables credit facility and would receive a portion of the proceeds from this offering if any outstanding borrowings under such credit facilities were to be repaid.&nbsp;&nbsp;If any one underwriter, together with its affiliates, were to receive 5% or more of the net proceeds of this offering by reason of the redemption or repayment, such underwriters would be deemed to have a &ldquo;conflict of interest&rdquo; within the meaning of Rule 5121 of the Financial Industry Regulatory Authority, Inc.&nbsp;&nbsp;(&ldquo;Rule 5121&rdquo;).&nbsp;&nbsp;Accordingly, this offering will be conducted in accordance with Rule 5121.&nbsp;&nbsp;No underwriter with a &ldquo;conflict of interest&rdquo; under Rule 5121 will confirm sales to any account over which it exercises discretion without the specific written approval of the account holder.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Risk Factors</B></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">See &ldquo;Risk Factors&rdquo; and the other information in this prospectus supplement and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as they may be amended, updated or modified in our reports filed with the SEC, which are incorporated by reference into this prospectus supplement, for a discussion of factors you should carefully consider before deciding to invest in the notes.</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Governing Law</B></TD>
    <TD STYLE="border-right: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">The indenture and the notes will be governed by, and construed in accordance with, the laws of the State of New York without application of principles of conflicts of law thereunder.&#9;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="border-bottom: Black 1pt solid; border-left: Black 1pt solid; padding-right: 5.4pt; padding-left: 5.4pt"><B>Trustee</B></TD>
    <TD STYLE="border-right: Black 1pt solid; border-bottom: Black 1pt solid; padding-right: 5.4pt; padding-bottom: 10pt; padding-left: 5.4pt">The Bank of New York Mellon.</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><B><A NAME="a_002" TITLE="risk_factors"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>You should carefully consider the risks described
below and in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as they may be amended, updated or modified in
our reports filed with the SEC, which are incorporated by reference into this prospectus supplement, before making a decision to invest
in our notes. The risks and uncertainties described below and in the documents incorporated by reference are not the only ones facing
our Company. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also materially adversely
affect our business and operations.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>If any of the matters included in the following
risks or the risks incorporated by reference were to occur, our business, financial condition, results of operations, cash flows or prospects
could be materially adversely affected. In such case, you may lose all or part of your original investment.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Secured indebtedness incurred by Quest Diagnostics will be effectively,
and existing and future obligations of our subsidiaries (including preferred stock) will be structurally, senior to the notes.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes are our senior unsecured obligations
and therefore will be effectively subordinated to our secured obligations to the extent of the value of the assets securing such obligations.
The notes will also be structurally subordinated to any existing and future indebtedness and other obligations of our subsidiaries. Our
subsidiaries are not guarantors of the notes. Certain of our domestic subsidiaries may be required to become subsidiary guarantors of
our existing debt securities issued prior to December 2019 if they incur or assume any indebtedness, subject to exceptions set forth in
the indenture governing the debt securities, or guarantee any indebtedness of our Company when the amount of such indebtedness, together
with any other outstanding indebtedness of our Company guaranteed by our subsidiaries that do not guarantee our existing debt securities,
exceeds $50 million in the aggregate at any time. To the extent the indenture governing the debt securities requires any domestic subsidiary
of our Company to guarantee our Company&rsquo;s existing debt securities issued under the indenture, any such subsidiary will be required
to guarantee the notes offered hereby in a substantially consistent manner for so long as such subsidiary guarantees such existing debt
securities. See &ldquo;Description of Notes&mdash;Future Subsidiary Guarantors.&rdquo; The indenture governing the notes does not limit
the amount of indebtedness that we can incur, but does limit the amount of indebtedness our subsidiaries who do not provide subsidiary
guarantees are permitted to incur. In addition, the indenture governing the notes limits the amount of secured indebtedness Quest Diagnostics
and its restricted subsidiaries may incur pursuant to the covenant described under the heading &ldquo;Description of Notes&mdash;Limitation
on Liens.&rdquo; This covenant is subject to important exceptions described under such heading. As of September 30, 2023, after giving
effect to this offering (as if the foregoing had occurred on that date), Quest Diagnostics would have had outstanding $286 million of
secured debt, all of which is secured indebtedness of our subsidiaries. As of September 30, 2023, $278 million of the secured indebtedness
consisted of borrowings outstanding under our secured receivables credit facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We conduct our operations through subsidiaries,
which generate a substantial portion of our operating income and cash flow. As a result, distributions or advances from our subsidiaries
are a major source of funds necessary to meet our debt service and other obligations. Contractual provisions, laws or regulations, as
well as any subsidiary&rsquo;s condition and operating requirements, may limit our ability to obtain cash required to pay our debt service
and other obligations. The notes will be structurally subordinated to all existing and future obligations of our subsidiaries, including
claims with respect to trade payables. As of September 30, 2023, after giving effect to this offering (as if the foregoing had occurred
on that date), our subsidiaries would have had debt outstanding of $286 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>If active trading markets for the notes do not develop, you may
not be able to resell them.</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes are new issues of securities for which
there currently are no trading markets. Although the underwriters have informed us that they intend to make markets in the notes, they
are not obligated to do so, and any such market-making activities may be discontinued at any time without notice. As a result, we cannot
provide any assurances that trading markets for the notes will ever develop or be maintained. Further, we can make no assurances as to
the liquidity of any markets that may develop for the notes, your ability to sell your notes or the prices at which you will be able to
sell your notes.</P>


<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Future trading prices of the notes will depend on many factors,
including prevailing interest rates, our financial condition and results of operations, the condition of the industry in which we operate
generally, the then-current ratings assigned to the notes and the market for similar securities. Accordingly, you may be required to bear
the financial risk of an investment in the notes for an indefinite period of time. We do not intend to apply for listing or quotation
of the notes on any securities exchange.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>


<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><B><A NAME="a_003" TITLE="safeharbor"></A>CAUTIONARY STATEMENT
FOR PURPOSES OF THE &ldquo;SAFE HARBOR&rdquo; PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Some statements and disclosures in this prospectus
supplement, or the accompanying prospectus and the documents incorporated herein or therein by reference, are forward-looking statements.
Forward-looking statements include our expected use of proceeds and all statements that do not relate solely to historical or current
facts and can be identified by the use of words such as &ldquo;may,&rdquo; &ldquo;believe,&rdquo; &ldquo;will,&rdquo; &ldquo;expect,&rdquo;
&ldquo;project,&rdquo; &ldquo;estimate,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;plan&rdquo; or &ldquo;continue.&rdquo; These forward-looking
statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our
plans and expectations, including actual results, to differ materially from the forward-looking statements. The Private Securities Litigation
Reform Act of 1995, or the Litigation Reform Act, provides a &ldquo;safe harbor&rdquo; for forward-looking statements to encourage companies
to provide prospective information about their companies without fear of litigation. We would like to take advantage of the &ldquo;safe
harbor&rdquo; provisions of the Litigation Reform Act in connection with the forward-looking statements included, or incorporated by reference,
in this document. Investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented,
or incorporated by reference, in this document. The following important factors could cause our actual financial results to differ materially
from those projected, forecasted or estimated by us in forward-looking statements:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(a)</TD><TD>Heightened competition from commercial clinical testing companies, IDNs, physicians and others.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(b)</TD><TD>Increased pricing pressure from customers, including payers and patients, and changing relationships with customers, payers, suppliers
or strategic partners.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(c)</TD><TD>A decline in economic conditions, including the impact of an inflationary environment.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(d)</TD><TD>Impact of changes in payment mix, including increased patient financial responsibility and any shift from fee-for-service to discounted,
capitated or bundled fee arrangements.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(e)</TD><TD>Adverse actions by government or other third-party payers, including healthcare reform that focuses on reducing healthcare costs but
does not recognize the value and importance to healthcare of clinical testing or innovative solutions, unilateral reduction of fee schedules
payable to us, unilateral recoupment of amounts allegedly owed and competitive bidding.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(f)</TD><TD>The impact upon our testing volume and collected revenue or general or administrative expenses resulting from compliance with policies
and requirements imposed by Medicare, Medicaid and other third-party payers. These include:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>the requirements of government and other payers to provide diagnosis codes and other information for many tests;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>inability to obtain from patients a valid advance consent form for tests that cannot be billed without prior receipt of the form;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(3)</TD><TD>the impact of additional or expanded limited coverage policies and limits on the allowable number of test units or ordering frequency
of same; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(4)</TD><TD>the impact of increased prior authorization programs.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(g)</TD><TD>Adverse results from pending or future government investigations, lawsuits or private actions. These include, in particular, monetary
damages, loss or suspension of licenses, and/or suspension or exclusion from the Medicare and Medicaid programs and/or criminal penalties.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(h)</TD><TD>Failure to efficiently integrate acquired businesses and to manage the costs related to any such integration, or to retain key technical,
professional or management personnel.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(i)</TD><TD>Denial, suspension or revocation of Clinical Laboratory Improvement Act (&ldquo;CLIA&rdquo;) certification or other licenses for any
of our clinical laboratories under the CLIA standards, revocation or suspension of the right to bill the Medicare and Medicaid programs
or other adverse regulatory actions by federal, state and local agencies.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(j)</TD><TD>Changes in and complexity of federal, state or local laws or regulations, including changes that result in new or increased federal
or state regulation of commercial clinical laboratories, tests developed by commercial clinical laboratories or other products or services
that we offer or activities in which we are engaged, including regulation by the U.S. Food and Drug Administration.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(k)</TD><TD>Inability to achieve expected benefits from our acquisitions of other businesses.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(l)</TD><TD>Inability to achieve additional benefits from our business performance tools and efficiency initiatives.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(m)</TD><TD>Adverse publicity and news coverage about the diagnostic information services industry or us.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(n)</TD><TD>Failure of the Company to maintain, defend and secure its financial, accounting, technology, customer data and other operational systems
from cyberattacks, IT system outages, telecommunications failures, malicious human acts and failure of the systems of third parties upon
which the Company relies.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(o)</TD><TD>Development of technologies that substantially alter the practice of clinical testing, including technology changes that lead to the
development of more convenient or cost-effective testing, or testing to be performed outside of a commercial clinical laboratory, such
as (1) point-of-care testing that can be performed by physicians in their offices, (2) advanced testing that can be performed by IDNs
in their own laboratories or (3) home testing that can be carried out without requiring the services of clinical laboratories.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(p)</TD><TD>Negative developments regarding intellectual property and other property rights that could prevent, limit or interfere with our ability
to develop, perform or sell our tests or operate our business. These include:</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>issuance of patents or other property rights to our competitors or others; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>inability to obtain or maintain adequate patent or other proprietary rights for our products and services or to successfully enforce
our proprietary rights.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(q)</TD><TD>Development of tests by our competitors or others which we may not be able to license, or usage (or theft) of our technology or similar
technologies or our trade secrets or other intellectual property by competitors, any of which could negatively affect our competitive
position.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(r)</TD><TD>Regulatory delay or inability to commercialize newly developed or licensed tests or technologies or to obtain appropriate reimbursements
for such tests.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(s)</TD><TD>The complexity of billing and revenue recognition for clinical laboratory testing.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(t)</TD><TD>Increases in interest rates and negative changes in our credit ratings from S&amp;P, Moody&rsquo;s or Fitch (each as defined in &ldquo;Description
of Notes&rdquo;) causing an unfavorable impact on our cost of or access to capital.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(u)</TD><TD>Inability to hire or retain qualified employees, including key senior management personnel.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(v)</TD><TD>Terrorist and other criminal activities, hurricanes, earthquakes or other natural disasters, and public health emergencies and health
pandemics, which could affect our customers or suppliers, transportation or systems, or our facilities, and for which insurance may not
adequately reimburse us.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(w)</TD><TD>Difficulties and uncertainties in the discovery, development, regulatory environment and/or marketing of new services or solutions
or new uses of existing tests.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(x)</TD><TD>Failure to adapt to changes in the healthcare system (including the medical laboratory testing market) and healthcare delivery, including
those stemming from the Protecting Access to Medicare Act, trends in utilization of the healthcare system and increased patient financial
responsibility for services.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(y)</TD><TD>Results and consequences of governmental inquiries.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(z)</TD><TD>Difficulty in implementing, or lack of success with, our strategic plan.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(aa)</TD><TD>The impact of healthcare data analysis on our industry and the ability of our Company to adapt to that impact.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.25in">(bb)</TD><TD>Failure to adequately operationalize appropriate controls around use of our data, including risk of non-compliance with privacy law
requirements.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">(cc) The COVID-19 pandemic.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><B><A NAME="a_004" TITLE="useproceeds"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We estimate that the net proceeds from this
offering of notes, after deducting underwriting discounts but before deducting other expenses of the offering, will be $744,727,500.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We expect to use the net proceeds for general
corporate purposes, which may include the redemption or repayment of indebtedness. The indebtedness we may redeem or repay includes our
$300 million aggregate principal amount of 4.25% Senior Notes and any outstanding borrowings under our senior unsecured revolving credit
facility and our secured receivables credit facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We may repay the 4.25% Senior Notes in full
at the April 1, 2024 maturity date or earlier redeem the 4.25% Senior Notes, in whole or in part, pursuant to their terms.&nbsp; As of
September 30, 2023, we had no borrowings outstanding under our senior unsecured revolving credit facility and our borrowing rate for Term
Secured Overnight Financing Rate (&ldquo;Term SOFR&rdquo;)-based loans thereunder was adjusted Term SOFR plus 1.00%. The senior unsecured
revolving credit facility matures in November 2026.&nbsp; As of September 30, 2023, we had $278 million in borrowings outstanding under
our secured receivables credit facility.&nbsp; The secured receivables credit facility, which was amended in October 2023, now matures
in October 2025 and interest on borrowings thereunder is based on the commercial paper rate for highly rated issuers or adjusted Term
SOFR, in each case plus 0.80%. See &ldquo;Underwriting (Conflicts of Interest)&mdash;Conflicts of Interest.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><A NAME="a_005" TITLE="capitalization"></A> <B>CAPITALIZATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following table sets forth our cash and
cash equivalents, debt and total capitalization at September 30, 2023 on an actual basis and as adjusted to reflect the issuance of the
notes offered hereby and assuming the net proceeds of this offering are not immediately applied to redeem or repay indebtedness. See &ldquo;Use
of Proceeds.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following table should be read together
with our unaudited interim consolidated financial statements and related notes and management&rsquo;s discussion and analysis of financial
condition and results of operations included in our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, which is incorporated
by reference into this prospectus supplement.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">September 30, 2023</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Actual</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">As Adjusted</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD><TD STYLE="font-weight: bold">&nbsp;</TD>
    <TD COLSPAN="7" STYLE="font-weight: bold; text-align: center">(in millions)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 56%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Cash and cash equivalents</TD><TD STYLE="width: 8%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right">143</TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="width: 8%; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="width: 1%; border-bottom: Black 1pt solid; text-align: left">$</TD><TD STYLE="width: 12%; border-bottom: Black 1pt solid; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">886</P></TD><TD STYLE="width: 1%; padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Debt (including current maturities):</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Secured receivables credit facility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">278</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">278</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Senior unsecured revolving credit facility</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">4.25% senior notes due 2024</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">302</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">302</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">3.50% senior notes due 2025</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">608</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">608</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">3.45% senior notes due 2026</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">506</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">506</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">4.20% senior notes due 2029</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">499</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">499</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">2.95% senior notes due 2030</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">799</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">799</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">2.80% senior notes due 2031</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">549</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">549</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">6.95% senior notes due 2037</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">175</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">5.75% senior notes due 2040</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">245</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">245</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">4.70% senior notes due 2045</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">300</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Senior notes offered hereby</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&mdash;&nbsp;&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">750</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="padding-bottom: 1pt; padding-left: 5.4pt">Other</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">8</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Debt issuance costs</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(19</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD><TD STYLE="font-size: 1pt; padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font-size: 1pt; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">(26</TD><TD STYLE="padding-bottom: 1pt; text-align: left">)</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total debt</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">4,250</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>4,993</B></P></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Stockholders&rsquo; equity:</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Quest Diagnostics stockholders&rsquo; equity</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,425</TD><TD STYLE="text-align: left">&nbsp;</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: right">6,425</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt">Noncontrolling interests</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">38</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD><TD STYLE="padding-bottom: 1pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: right">38</TD><TD STYLE="padding-bottom: 1pt; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total stockholders&rsquo; equity</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,463</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">6,463</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-weight: bold; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt">Total capitalization</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">10,713</TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>11,456</B></P></TD><TD STYLE="padding-bottom: 2.5pt; font-weight: bold; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B><A NAME="a_006" TITLE="descriptionofnotes"></A>DESCRIPTION OF NOTES</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The 6.400% senior notes due 2033 (the
&ldquo;Notes&rdquo;) will be issued under an indenture, dated as of June 27, 2001, as supplemented by the first supplemental
indenture, dated as of June 27, 2001, each among Quest Diagnostics, as issuer, the Initial Subsidiary Guarantors (as defined
therein), as guarantors, and The Bank of New York, as trustee, as further supplemented by the second supplemental indenture, dated
as of November 26, 2001, among Quest Diagnostics, the Subsidiary Guarantors (as defined therein) and The Bank of New York, as
further supplemented by the third supplemental indenture, dated as of April 4, 2002, among Quest Diagnostics, the Additional
Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented by the fourth supplemental indenture,
dated as of March 19, 2003, among Quest Diagnostics, the Additional Subsidiary Guarantor (as defined therein) and The Bank of New
York, as further supplemented by the fifth supplemental indenture, dated as of April 16, 2004, among Quest Diagnostics, the
Additional Subsidiary Guarantor (as defined therein) and The Bank of New York, as further supplemented by the sixth supplemental
indenture, dated as of October 31, 2005, among Quest Diagnostics, the Subsidiary Guarantors (as defined therein) and The Bank of New
York, as further supplemented by the seventh supplemental indenture, dated as of November 21, 2005, among Quest Diagnostics, the
Additional Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented by the eighth supplemental
indenture, dated as of July 31, 2006, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The
Bank of New York, as further supplemented by the ninth supplemental indenture, dated as of September 30, 2006, among Quest
Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented by the
tenth supplemental indenture, dated as of June 22, 2007, among Quest Diagnostics, the Subsidiary Guarantors (as defined therein) and
The Bank of New York, as further supplemented by the eleventh supplemental indenture, dated as of June 22, 2007, among Quest
Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented by the
twelfth supplemental indenture, dated as of June 25, 2007, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined
therein) and The Bank of New York, as further supplemented by the thirteenth supplemental indenture, dated as of November 17, 2009,
among Quest Diagnostics, the Subsidiary Guarantors (as defined therein) and The Bank of New York Mellon, as further supplemented by
the fourteenth supplemental indenture, dated as of March 24, 2011, among Quest Diagnostics, the Subsidiary Guarantors (as defined
therein) and The Bank of New York Mellon, as further supplemented by the fifteenth supplemental indenture, dated as of November 30,
2011, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The Bank of New York Mellon, as further
supplemented by the sixteenth supplemental indenture, dated as of March 17, 2014, between Quest Diagnostics and The Bank of New York
Mellon, as further supplemented by the seventeenth supplemental indenture, dated as of March 10, 2015, between Quest Diagnostics and
The Bank of New York Mellon, as further supplemented by the eighteenth supplemental indenture, dated as of May 26, 2016, between
Quest Diagnostics and The Bank of New York Mellon, as further supplemented by the nineteenth supplemental indenture, dated as of
March 12, 2019, between Quest Diagnostics and The Bank of New York Mellon, as further supplemented by the twentieth supplemental
indenture, dated as of December 16, 2019, between Quest Diagnostics and The Bank of New York Mellon, as further supplemented by the
twenty-first supplemental indenture, dated as of May 13, 2020, between Quest Diagnostics and The Bank of New York Mellon, and as to
be further supplemented by the twenty-second supplemental indenture between Quest Diagnostics and The Bank of New York Mellon, to be
dated as of the closing date of this offering (collectively, as so supplemented, the &ldquo;Indenture&rdquo;). The terms of the
Notes include those stated in the Indenture and those made part of the Indenture by reference to the Trust Indenture Act of 1939, as
amended (the &ldquo;Trust Indenture Act&rdquo;). A copy of the Indenture (other than the twenty-second supplemental indenture, to be
dated as of the closing date of this offering) has been filed as an exhibit to Quest Diagnostics&rsquo; Annual Report on Form 10-K
for the fiscal year ended December 31, 2022 incorporated by reference into this prospectus supplement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Whenever we refer in this &ldquo;Description
of Notes&rdquo; to terms defined in the Indenture below, such defined terms are incorporated herein by reference. As used in this &ldquo;Description
of Notes,&rdquo; the terms &ldquo;we,&rdquo; &ldquo;our,&rdquo; &ldquo;us&rdquo; and &ldquo;Quest Diagnostics&rdquo; do not include any
current or future subsidiary of Quest Diagnostics Incorporated, unless the context indicates otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>General</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will be initially limited to
$750,000,000 aggregate principal amount and will mature and become due and payable, together with any accrued and unpaid interest
thereon, on November 30, 2033.</P>


<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics may from time to time, without
the consent of the holders of the Notes, issue additional Notes having the same ranking and the same interest rate, maturity and other
terms (except the issue date, public offering price and, if applicable, initial interest payment date) as the Notes. Any additional Notes
and the Notes will generally constitute a single series under the Indenture. This type of offering is often referred to as a &ldquo;re-opening.&rdquo;
Additional Notes may constitute a separate issuance for U.S. federal income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Interest</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will bear interest at the annual
rate noted on the cover page of this prospectus supplement. Interest on the Notes will be payable semiannually on May 30 and
November 30 of each year, beginning May 30, 2024. Interest on the Notes will be paid to holders of record on May 15 or November
15 immediately before the applicable interest payment date. Interest will accrue from
November 1, 2023 and will be computed on the basis of a 360-day year of twelve
30-day months.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If any interest payment date, redemption date
or maturity date falls on a day that is not a business day, the payment due on that interest payment date, redemption date or maturity
date will be made on the next succeeding business day, and without any interest or other payment in respect of such delay.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Seniority; Ranking</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will be senior unsecured obligations
of Quest Diagnostics and will rank equally with other existing and future senior unsecured obligations of Quest Diagnostics. As of September
30, 2023, after giving effect to this offering (as if the foregoing had occurred on that date), Quest Diagnostics would have had total
debt outstanding of $4,993 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will be effectively subordinated to
any secured obligations of Quest Diagnostics to the extent of the value of the assets securing such obligations. The Indenture does not
limit the amount of indebtedness that Quest Diagnostics can incur, but does limit the amount of indebtedness its subsidiaries that do
not guarantee the Notes are permitted to incur (as described below). In addition, the Indenture limits the amount of secured indebtedness
both Quest Diagnostics and its Restricted Subsidiaries may incur pursuant to the covenant described under the heading &ldquo;&mdash;Limitation
on Liens.&rdquo; This covenant is subject to important exceptions described under such heading. As of September 30, 2023, after giving
effect to this offering (as if the foregoing had occurred on that date), on a consolidated basis, Quest Diagnostics would have had secured
debt outstanding of $286 million, all of which is secured indebtedness of our subsidiaries. As of September 30, 2023, $278 million of
the secured indebtedness consisted of borrowings outstanding under our secured receivables credit facility.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics conducts its operations through
subsidiaries, which generate a substantial portion of its operating income and cash. As a result, distributions or advances from subsidiaries
of Quest Diagnostics are a major source of funds necessary to meet its debt service and other obligations. Contractual provisions, laws
or regulations, as well as any subsidiary&rsquo;s financial condition and operating requirements, may limit the ability of Quest Diagnostics
to obtain cash required to pay Quest Diagnostics&rsquo; debt service obligations, including payments on the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will be structurally subordinated
to all existing and future obligations of Quest Diagnostics&rsquo; subsidiaries, including claims with respect to trade payables. The
subsidiaries of Quest Diagnostics are limited in the amount of Indebtedness they are permitted to incur pursuant to the covenant described
under &ldquo;&mdash;Limitation on Subsidiary Indebtedness and Preferred Stock.&rdquo; This covenant is subject to important exceptions
described under such heading. As of September 30, 2023, after giving effect to this offering (as if the foregoing had occurred on that
date), the subsidiaries of Quest Diagnostics would have had outstanding $286 million of debt, all of which was secured.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Our subsidiaries are not guarantors of the Notes.
Certain of our domestic subsidiaries may be required to become subsidiary guarantors of our existing debt securities issued prior to December
2019 if they incur or assume any Indebtedness, subject to exceptions set forth in the Indenture, or guarantee any Indebtedness of our
Company when the amount of such Indebtedness, together with any other outstanding Indebtedness of our Company guaranteed by our subsidiaries
that do not guarantee our existing debt securities, exceeds $50 million in the aggregate at any time.</P>


<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">To the extent the Indenture requires any domestic Subsidiary of
our Company to guarantee our Company&rsquo;s existing debt securities issued under the Indenture prior to December 2019, any such Subsidiary
will be required to guarantee the Notes in a substantially consistent manner for so long as such Subsidiary guarantees such existing debt
securities. See &ldquo;&mdash;Future Subsidiary Guarantors.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Optional Redemption</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Prior to August
30, 2033 (three months
prior to their maturity date) (the &ldquo;Par Call Date&rdquo;), we may redeem the Notes at our option, in whole or in part, at any
time and from time to time, at a redemption price (expressed as a percentage of principal amount and rounded to three decimal
places) equal to the greater of:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(1) (a) the sum of the present values of the
remaining scheduled payments of principal and interest thereon discounted to the redemption date (assuming the Notes matured on the Par
Call Date) on a semi-annual basis (assuming a 360-day year consisting of twelve 30-day months) at the Treasury Rate (as defined below
in this prospectus supplement) plus 25 basis points less
(b) interest accrued to the date of redemption, and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(2) 100% of the principal amount of the Notes
to be redeemed,</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">plus, in either case, accrued and unpaid interest thereon to the
redemption date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">On or after the Par Call Date, we may redeem
the Notes, in whole or in part, at any time and from time to time, at a redemption price equal to 100% of the principal amount of the
Notes being redeemed plus accrued and unpaid interest thereon to the redemption date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">&ldquo;Treasury Rate&rdquo; means, with respect
to any redemption date, the yield determined by Quest Diagnostics in accordance with the following two paragraphs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">The Treasury Rate shall be determined by Quest
Diagnostics after 4:15 p.m., New York City time (or after such time as yields on U.S. government securities are posted daily by the Board
of Governors of the Federal Reserve System), on the third business day preceding the redemption date based upon the yield or yields for
the most recent day that appear after such time on such day in the most recent statistical release published by the Board of Governors
of the Federal Reserve System designated as &ldquo;Selected Interest Rates (Daily) - H.15&rdquo; (or any successor designation or publication)
(&ldquo;H.15&rdquo;) under the caption &ldquo;U.S. government securities&ndash;Treasury constant maturities&ndash;Nominal&rdquo; (or any
successor caption or heading) (&ldquo;H.15 TCM&rdquo;). In determining the Treasury Rate, Quest Diagnostics shall select, as applicable:
(1) the yield for the Treasury constant maturity on H.15 exactly equal to the period from the redemption date to the Par Call Date (the
&ldquo;Remaining Life&rdquo;); or (2) if there is no such Treasury constant maturity on H.15 exactly equal to the Remaining Life, the
two yields &ndash; one yield corresponding to the Treasury constant maturity on H.15 immediately shorter than and one yield corresponding
to the Treasury constant maturity on H.15 immediately longer than the Remaining Life &ndash; and shall interpolate to the Par Call Date
on a straight-line basis (using the actual number of days) using such yields and rounding the result to three decimal places; or (3) if
there is no such Treasury constant maturity on H.15 shorter than or longer than the Remaining Life, the yield for the single Treasury
constant maturity on H.15 closest to the Remaining Life. For purposes of this paragraph, the applicable Treasury constant maturity or
maturities on H.15 shall be deemed to have a maturity date equal to the relevant number of months or years, as applicable, of such Treasury
constant maturity from the redemption date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">If on the third business day preceding the redemption
date H.15 TCM is no longer published, Quest Diagnostics shall calculate the Treasury Rate based on the rate per annum equal to the semi-annual
equivalent yield to maturity at 11:00 a.m., New York City time, on the second business day preceding such redemption date of the United
States Treasury security maturing on, or with a maturity that is closest to, the Par Call Date, as applicable. If there is no United States
Treasury security maturing on the Par Call Date but there are two or more United States Treasury securities with a maturity date equally
distant from the Par Call Date, one with a maturity date preceding the Par Call Date and one with a maturity date following the Par Call
Date, Quest Diagnostics shall select the United States Treasury security with a maturity date preceding the Par Call Date. If there are
two or more United States Treasury securities maturing on the Par Call Date or two or more United States Treasury securities meeting the
criteria of the preceding sentence, Quest Diagnostics shall select from among these two or more United States Treasury securities the
United States Treasury security that is trading closest to par based upon the average of the bid and asked prices for such United States
Treasury securities at 11:00 a.m., New York City time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt">In determining the Treasury Rate in accordance with the terms of
this paragraph, the semi-annual yield to maturity of the applicable United States Treasury security shall be based upon the average of
the bid and asked prices (expressed as a percentage of principal amount) at 11:00 a.m., New York City time, of such United States Treasury
security, and rounded to three decimal places.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Quest Diagnostics&rsquo; actions and determinations
in determining the redemption price shall be conclusive and binding for all purposes, absent manifest error.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Notice of any redemption will be mailed or electronically
delivered (or otherwise transmitted in accordance with the depositary&rsquo;s procedures) at least 10 days but not more than 60 days before
the redemption date to each holder of Notes to be redeemed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">In the case of a partial redemption, selection
of the Notes for redemption will be made pro rata, by lot or by such other method as the trustee in its sole discretion deems appropriate
and fair. No Notes of a principal amount of $2,000 or less will be redeemed in part. If any note is to be redeemed in part only, the notice
of redemption that relates to the note will state the portion of the principal amount of the note to be redeemed. A new note in a principal
amount equal to the unredeemed portion of the note will be issued in the name of the holder of the note upon surrender for cancellation
of the original note. For so long as the Notes are held by DTC (or another depositary), the redemption of the Notes shall be done in accordance
with the policies and procedures of the depositary, which may be made on a pro rata pass-through distribution of principal basis.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-indent: 0.5in">Unless Quest Diagnostics defaults in payment
of the redemption price, on and after the redemption date interest will cease to accrue on the Notes or portions thereof called for redemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Change of Control</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If a Change of Control Triggering Event occurs,
unless Quest Diagnostics has exercised its option to redeem the Notes as described above, Quest Diagnostics will be required to make an
offer (the &ldquo;Change of Control Offer&rdquo;) to each holder of the Notes to repurchase all or any part (equal to $2,000 or an integral
multiple of $1,000 in excess thereof) of that holder&rsquo;s Notes on the terms set forth in the Notes. In the Change of Control Offer,
Quest Diagnostics will be required to offer payment in cash equal to 101% of the aggregate principal amount of Notes repurchased, plus
accrued and unpaid interest, if any, on the Notes repurchased to the repurchase date (the &ldquo;Change of Control Payment&rdquo;). Within
30 days following any Change of Control Triggering Event or, at Quest Diagnostics&rsquo; option, prior to any Change of Control, but after
public announcement of the transaction that constitutes or may constitute the Change of Control, a notice will be mailed to holders of
the Notes describing the transaction that constitutes or may constitute the Change of Control Triggering Event and offering to repurchase
the Notes on the date specified in the notice, which date will be no earlier than 30 days and no later than 60 days from the date such
notice is mailed (the &ldquo;Change of Control Payment Date&rdquo;). The notice will, if mailed prior to the date of consummation of the
Change of Control, state that the offer to purchase is conditioned on the Change of Control Triggering Event occurring on or prior to
the Change of Control Payment Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">On the Change of Control Payment Date, Quest
Diagnostics will, to the extent lawful:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>accept for payment all Notes or portions of Notes properly tendered pursuant to the Change of Control Offer;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>deposit with the paying agent an amount equal to the Change of Control Payment in respect of all Notes or portions of Notes properly
tendered; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>deliver or cause to be delivered to the trustee the Notes properly accepted together with an Officers&#146; Certificate stating the
aggregate principal amount of Notes or portions of Notes being repurchased.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics will not be required to make
a Change of Control Offer upon the occurrence of a Change of Control Triggering Event if a third party makes such an offer in the manner,
at the times and otherwise in compliance with the requirements for an offer made by Quest Diagnostics and the third party repurchases
all Notes properly tendered and not withdrawn under its offer. In addition, Quest Diagnostics will not repurchase any Notes if there has
occurred and is continuing on the Change of Control Payment Date an event of default under the Indenture, other than a default in the
payment of the Change of Control Payment upon a Change of Control Triggering Event.</P>


<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics will comply with the requirements
of Rule 14e-1 under the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;), and any other securities laws and
regulations thereunder to the extent those laws and regulations are applicable in connection with the repurchase of the Notes as a result
of a Change of Control Triggering Event. To the extent that the provisions of any such securities laws or regulations conflict with the
Change of Control Offer provisions of the Notes, Quest Diagnostics will comply with those securities laws and regulations and will not
be deemed to have breached its obligations under the Change of Control Offer provisions of the Notes by virtue of any such conflict. For
purposes of the Change of Control Offer provisions of the Notes, the following terms will be applicable:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Change of Control&rdquo; means the occurrence
of any of the following: (1) the consummation of any transaction (including, without limitation, any merger or consolidation) the result
of which is that any &ldquo;person&rdquo; (as that term is used in Section 13(d) (3) of the Exchange Act) (other than Quest Diagnostics
or one of its subsidiaries) becomes the beneficial owner (as defined in Rules 13d-3 and 13d-5 under the Exchange Act), directly or indirectly,
of more than 50% of the voting stock of Quest Diagnostics or other voting stock into which the voting stock of Quest Diagnostics is reclassified,
consolidated, exchanged or changed, measured by voting power rather than number of shares; (2) the direct or indirect sale, transfer,
conveyance or other disposition (other than by way of merger or consolidation), in one or more series of related transactions, of all
or substantially all of Quest Diagnostics&rsquo; assets and the assets of its subsidiaries, taken as a whole, to one or more &ldquo;persons&rdquo;
(as that term is defined in the Indenture) (other than Quest Diagnostics or one of its subsidiaries); or (3) the first day on which a
majority of the members of the Board of Directors of Quest Diagnostics are not Continuing Directors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Notwithstanding the foregoing, a transaction
will not be deemed to involve a Change of Control if (1) Quest Diagnostics becomes a direct or indirect wholly-owned subsidiary of a holding
company and (2)(A) the direct or indirect holders of the voting stock of such holding company immediately following that transaction are
substantially the same as the holders of the voting stock of Quest Diagnostics immediately prior to that transaction or (B) immediately
following that transaction no person (other than a holding company satisfying the requirements of this sentence) is the beneficial owner,
directly or indirectly, of more than 50% of the voting stock of such holding company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Change of Control Triggering Event&rdquo;
means the occurrence of both a Change of Control and a Rating event.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Continuing Directors&rdquo; means, as
of any date of determination, any member of Quest Diagnostics&rsquo; Board of Directors who (1) was a member of such Board of Directors
on the date the Notes were issued or (2) was nominated for election, elected or appointed to such Board of Directors with the approval
of a majority of the Continuing Directors who were members of such Board of Directors at the time of such nomination, election or appointment
(either by a specific vote or by approval of the proxy statement of Quest Diagnostics in which such member was named as a nominee for
election as a director, without objection to such nomination).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Fitch&rdquo; means Fitch Ratings, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Investment Grade Rating&rdquo; means
a rating equal to or higher than Baa3 (or the equivalent) by Moody&rsquo;s, BBB&#8722; (or the equivalent) by S&amp;P and BBB&#8722; (or
the equivalent) by Fitch, and the equivalent investment grade credit rating from any additional rating agency or Rating Agencies selected
by Quest Diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Moody&rsquo;s&rdquo; means Moody&rsquo;s
Investors Service, Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Rating Agencies&rdquo; means (1) each
of Moody&rsquo;s, S&amp;P and Fitch; and (2) if any of Moody&rsquo;s, S&amp;P or Fitch ceases to rate the Notes or fails to make a rating
of the Notes publicly available for reasons outside of the control of Quest Diagnostics, a &ldquo;nationally recognized statistical rating
organization&rdquo; within the meaning of Section 3(a)(62) of the Exchange Act selected by Quest Diagnostics (as certified by a resolution
of the Board of Directors) as a replacement agency for Moody&rsquo;s, S&amp;P or Fitch, or all of them, as the case may be.</P>


<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Rating event&rdquo; means the rating
on the Notes is lowered by at least two of the Rating Agencies and the Notes are rated below an Investment Grade Rating by at least two
of the Rating Agencies on any day within the 60-day period (which 60-day period will be extended so long as the rating of the Notes is
under publicly announced consideration for a possible downgrade by any of the Rating Agencies) after the earlier of (1) the occurrence
of a Change of Control and (2) public notice of the occurrence of a Change of Control or the intention of Quest Diagnostics to effect
a Change of Control; <I>provided</I>, <I>however</I>, that a Rating event otherwise arising by virtue of a particular reduction in rating
will not be deemed to have occurred in respect of a particular Change of Control (and thus will not be deemed a Rating event for purposes
of the definition of Change of Control Triggering Event) if the Rating Agencies making the reduction in rating to which this definition
would otherwise apply do not announce or publicly confirm or inform the trustee in writing at its request or the request of Quest Diagnostics
that the reduction was the result, in whole or in part, of any event or circumstance comprised of or arising as a result of, or in respect
of, the applicable Change of Control (whether or not the applicable Change of Control has occurred at the time of the Rating event).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;S&amp;P&rdquo; means S&amp;P Global Ratings,
a division of S&amp;P Global Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Voting stock&rdquo; means, with respect
to any specified &ldquo;person&rdquo; (as that term is used in Section 13(d)(3) of the Exchange Act) as of any date, the capital stock
of such person that is at the time entitled to vote generally in the election of the board of directors of such person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Sinking Fund</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will not be entitled to the benefit
of any sinking fund.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Limitation on Liens</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Other than as provided under &ldquo;&mdash;Exempted
Liens and Sale and Leaseback Transactions,&rdquo; Quest Diagnostics will not, and will not permit any Restricted Subsidiary to, create
or assume any Indebtedness secured by any Lien on any Principal Property or shares of stock or Indebtedness of any Restricted Subsidiary,
unless: (1) in the case of Quest Diagnostics, the Notes are secured by such Lien equally and ratably with, or prior to, the Indebtedness
secured by such Lien, or (2) in the case of any domestic Subsidiary that has guaranteed the Notes, such Subsidiary&rsquo;s guarantee of
the Notes is secured by such Lien equally and ratably with, or prior to, the Indebtedness secured by such Lien. The restrictions do not
apply to Indebtedness that is secured by:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens existing on the date of the issuance of the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens securing only the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens in favor of only Quest Diagnostics or any Restricted Subsidiary;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens on property or shares of stock or indebtedness of a Person existing at the time such Person becomes a Restricted Subsidiary
or is merged into or consolidated with, or its assets are acquired by, Quest Diagnostics or any Restricted Subsidiary (<I>provided</I>
that such Lien was not incurred in anticipation of such transaction and was in existence prior to such transaction) so long as such Lien
does not extend to any other property and the Indebtedness so secured is not increased;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens on property existing immediately prior to the acquisition thereof (<I>provided</I> that such Lien was not incurred in anticipation
of such transaction and was in existence prior to such transaction) so long as such Lien does not extend to any other property and the
Indebtedness so secured is not increased;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens to secure Indebtedness incurred for the purpose of financing all or any part of a property&#146;s purchase price or cost of
construction or additions, repairs, alterations, or other improvements; <I>provided</I> that (1) the principal amount of any Indebtedness
secured by such Lien does not exceed 100% of such property&#146;s purchase price or cost, (2) such Lien does not extend to or cover any</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">other property other than the property so purchased, constructed
or on which such additions, repairs, alterations or other improvements were so made, and (3) such Lien is incurred prior to or within
270 days after the acquisition of such property or the completion of construction or such additions, repairs, alterations or other improvements
and the full operation of such property thereafter;</P>


<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens in favor of the United States or any state thereof, or any instrumentality of either, to secure certain payments pursuant to
any contract or statute;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens for taxes or assessments or other governmental charges or levies which are being contested in good faith and for which adequate
reserves are being maintained, to the extent required by generally accepted accounting principles;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>title exceptions, easements and other similar Liens that are not consensual and that do not materially impair the use of the property
subject thereto;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens to secure obligations under workmen&#146;s compensation laws, unemployment compensation, old-age pensions and other social security
benefits or similar legislation, including Liens with respect to judgments which are not currently dischargeable;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens arising out of legal proceedings, including Liens arising out of judgments or awards;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>warehousemen&#146;s, materialmen&#146;s and other similar Liens for sums being contested in good faith and for which adequate reserves
are being maintained, to the extent required by generally accepted accounting principles;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens incurred to secure the performance of statutory obligations, surety or appeal bonds, performance or return-of-money bonds or
other obligations of a like nature incurred in the ordinary course of business; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Liens to secure any extension, renewal, refinancing or refunding (or successive extensions, renewals, refinancings or refundings),
in whole or in part, of any Indebtedness secured by Liens referred to in the foregoing bullets or liens created in connection with any
amendment, consent or waiver relating to such Indebtedness, so long as such Lien does not extend to any other property and the Indebtedness
so secured does not exceed the fair market value (as determined by our board of directors) of the assets subject to such Liens at the
time of such extension, renewal, refinancing or refunding, or such amendment, consent or waiver, as the case may be.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Limitation on Sale and Leaseback Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Other than as provided under &ldquo;&mdash;Exempted
Liens and Sale and Leaseback Transactions,&rdquo; Quest Diagnostics will not, and will not permit any Restricted Subsidiary to, enter
into any Sale and Leaseback Transaction with respect to any Principal Property unless:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>the Sale and Leaseback Transaction is solely with Quest Diagnostics or a domestic Subsidiary that has guaranteed the Notes; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>the lease is for a period not in excess of five years, including renewal rights; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quest Diagnostics or the Restricted Subsidiary, prior to or within 270 days after the sale of such Principal Property in connection
with the Sale and Leaseback Transaction is completed, applies the net cash proceeds of the sale of the Principal Property leased to:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>the retirement of the Notes or debt ranking equally with the Notes of Quest Diagnostics or any Restricted Subsidiary, or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>the acquisition of different property, facilities or equipment or the expansion of Quest Diagnostics&rsquo; existing business, including
the acquisition of other businesses.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Exempted Liens and Sale and Leaseback Transactions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Notwithstanding the restrictions described under
the headings &ldquo;&mdash;Limitation on Liens&rdquo; or &ldquo;&mdash;Limitation on Sale and Leaseback Transactions,&rdquo; Quest Diagnostics
or any Restricted Subsidiary may create or assume any Liens or enter into any Sale and Leaseback Transactions not otherwise permitted
as described above, if the sum of the following does not exceed 10% of Consolidated Total Assets:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>the outstanding Indebtedness secured by such Liens (not including any Liens permitted under &#147;- Limitation on Liens&#148; which
amount does not include any Liens permitted under the provisions of this &#147;-Exempted Liens and Sale and Leaseback Transactions&#148;);
plus</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>all Attributable Debt in respect of such Sale and Leaseback Transaction entered into (not including any Sale and Leaseback Transactions
permitted under &#147;-Limitation on Sale and Leaseback Transactions&#148; which amount does not include any Sale and Leaseback Transactions
permitted under the provisions of this &#147;-Exempted Liens and Sale and Leaseback Transactions&#148;),</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">measured, in each case, at the time such Lien is incurred or any
such Sale and Leaseback Transaction is entered into by Quest Diagnostics or the Restricted Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Limitation on Subsidiary Indebtedness and Preferred Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">None of the Subsidiaries of Quest Diagnostics
other than a domestic Subsidiary that has guaranteed the Notes may, directly or indirectly, create, incur, issue, assume or extend the
maturity of any Indebtedness (including Acquired Indebtedness) or Preferred Stock except for the following, <I>provided</I> that, for
purposes of this covenant, any Acquired Indebtedness shall not be deemed to have been incurred until 270 days from the date (1) the Person
obligated on such Acquired Indebtedness becomes a Subsidiary of Quest Diagnostics or (2) the acquisition of assets, in connection with
which such Acquired Indebtedness was assumed, is consummated:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Indebtedness outstanding on the date of the Indenture;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Indebtedness representing the assumption by one Subsidiary of Indebtedness of another Subsidiary;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Indebtedness outstanding under any Receivables Credit Facility;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Indebtedness secured by a Lien incurred for the purpose of financing all or any part of a property&#146;s purchase price or cost of
construction or additions, repairs, alterations or other improvements, <I>provided</I> that such Indebtedness and Lien is incurred prior
to or within 270 days after the acquisition of such property or the completion of construction or such additions, repairs, alterations
or other improvements and the full operation of such property thereafter;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Indebtedness of any Subsidiary of Quest Diagnostics, the proceeds of which are used to renew, extend, refinance or refund outstanding
Indebtedness of such Subsidiary; <I>provided</I> that such Indebtedness is scheduled to mature no earlier than the Indebtedness being
renewed, extended, refinanced or refunded; <I>provided further</I> that such Indebtedness shall be permitted hereunder only to the extent
that the aggregate principal amount of such Indebtedness (or, if such Indebtedness is issued at a price less than the principal amount
thereof, the aggregate amount of gross proceeds therefrom) does not exceed the aggregate principal amount then outstanding under the Indebtedness
being renewed, extended, refinanced or refunded (or if the Indebtedness being renewed, extended, refinanced or refunded, was issued at
a price less than the principal amount thereof, then not in excess of the amount of liability in respect thereof determined in accordance
with generally accepted accounting principles) plus the lesser of (A) the stated amount of any premium or other payment required to be
paid in connection with such a refinancing pursuant to the terms of the Indebtedness being refinanced or (B) the amount of premium or
other payment actually paid at such time to refinance the Indebtedness, plus, in either case, the amount of expenses of such Subsidiary
incurred in connection with such refinancing;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Indebtedness of a Subsidiary of Quest Diagnostics to Quest Diagnostics or to another Subsidiary of Quest Diagnostics;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>any Indebtedness resulting from a Sale and Leaseback Transaction which is permitted by the &#147;-Limitation on Sale and Leaseback
Transactions&#148; covenant (but not including any Sale and Leaseback Transaction which is permitted by the &#147;-Exempted Liens and
Sale and Leaseback Transactions&#148; provisions relating thereto);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>any Permitted Acquired Indebtedness;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>any guarantee of Indebtedness of Quest Diagnostics by any Subsidiary of Quest Diagnostics in anticipation of such Subsidiary guaranteeing
the obligations of Quest Diagnostics pursuant to the terms of the Indenture;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Preferred Stock to the extent that the aggregate liquidation preference of Preferred Stock, outstanding at any one time, does not
exceed 5% of Consolidated Total Assets;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>shares of Preferred Stock held by Quest Diagnostics or a subsidiary of Quest Diagnostics; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>any Indebtedness, including any Acquired Indebtedness that is not Permitted Acquired Indebtedness, the outstanding aggregate principal
amount of which does not at any one time exceed the greater of (1) 10% of Consolidated Total Assets or (2) $200 million, measured in each
case at the time such Indebtedness is incurred.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 21 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Merger, Consolidation or Sale of Assets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Quest Diagnostics may merge or consolidate with
another Person and may sell, transfer or lease all or substantially all of its assets to another Person if all the following conditions
are met:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>The merger, consolidation or sale of assets must not cause an event of default. See &#147;-Events of Default.&#148; An event of default
for this purpose would also include any event that would be an event of default if the notice or time requirements were disregarded;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>If Quest Diagnostics is not the surviving entity, the Person we would merge or consolidate with, or sell all or substantially all
of our assets to, must be organized under the laws of the United States or any state thereof;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>If Quest Diagnostics is not the surviving entity, the Person we would merge or consolidate with, or sell all or substantially all
of our assets to, must expressly assume by supplemental indenture all of our obligations under the Notes and the Indenture; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quest Diagnostics must deliver specific certification and documents to the trustee.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Events of Default</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The term &ldquo;Event of Default&rdquo; in respect
of the Notes means any of the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quest Diagnostics or any domestic Subsidiary that guarantees the obligations of Quest Diagnostics pursuant to the terms of the Indenture
does not pay the principal of or any premium on the Notes on its due date;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quest Diagnostics or any domestic Subsidiary that guarantees the obligations of Quest Diagnostics pursuant to the terms of the Indenture
does not pay interest on the Notes within 30 days of its due date whether at maturity, upon redemption or upon acceleration;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quest Diagnostics or any domestic Subsidiary that guarantees the obligations of Quest Diagnostics pursuant to the terms of the Indenture
remains in breach of a covenant in respect of the Notes for 60 days after it receives a written notice of default stating it is in breach
and requiring that it remedy the breach. The notice must be sent by either the trustee or holders of 25% of the aggregate principal amount
of the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>An event of default under any indenture or instrument evidencing or under which Quest Diagnostics or any domestic Subsidiary that
guarantees the obligations of Quest Diagnostics pursuant to the terms of the Indenture then has outstanding any Indebtedness shall occur
and be continuing and either:</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(1)</TD><TD>such event of default results from the failure to pay the principal of such Indebtedness in excess of $200 million at final maturity
of such Indebtedness, individually or in the aggregate; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 10pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in">(2)</TD><TD>as a result of such event of default the maturity of such Indebtedness shall have been accelerated so that the same shall be or become
due and payable prior to the date on which the same would otherwise have become due and payable and the principal amount of such Indebtedness,
together with the principal of any other Indebtedness of Quest Diagnostics or such Subsidiary in default, or the maturity of which has
been accelerated, aggregates at least $200 million, individually or in the aggregate;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Any domestic Subsidiary that guarantees the obligations of Quest Diagnostics pursuant to the terms of the Indenture repudiates its
obligations under its guarantee of the Notes or, other than by reason of the termination of the Indenture or the release of any such guarantee
in accordance with the Indenture, any such guarantee ceases to be in full force and effect or is declared null and void and such condition
shall have continued for a period of 30 days after written notice of such failure requiring Quest Diagnostics or such Subsidiary to remedy
the same shall have been given to Quest Diagnostics by the trustee or to Quest Diagnostics and the trustee by the holders of 25% in aggregate
principal amount of the Notes then outstanding; or</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 22 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Quest Diagnostics or any domestic Subsidiary that guarantees the obligations of Quest Diagnostics pursuant to the terms of the Indenture
files for bankruptcy or certain other events of bankruptcy, insolvency or reorganization occur.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The trustee may withhold notice to the holders
of Notes of any default (except in the payment of principal or interest) if it considers such withholding of notice to be in the best
interests of the holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If an event of default with respect to the Notes
has occurred and has not been cured, the trustee or the holders of 25% in aggregate principal amount of the Notes may declare the entire
principal amount (and premium, if any) of, and all the accrued interest on the Notes to be due and immediately payable. This is called
a declaration of acceleration of maturity. If an event of default with respect to the Notes occurs because of certain events in bankruptcy,
insolvency or reorganization, the principal amount of the Notes will be automatically accelerated, without any action by the trustee or
any holder. Holders of a majority in principal amount of the Notes may also waive certain past defaults under the Indenture on behalf
of all of the holders of the Notes. A declaration of acceleration of maturity with respect to the Notes may be canceled, under specific
circumstances, by the holders of at least a majority in principal amount of the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Except in cases of default, where the trustee
has some special duties, the trustee is not required to take any action under the Indenture at the request of any of the holders unless
the holders offer the trustee protection reasonably satisfactory to it from expenses and liability called an &ldquo;indemnity.&rdquo;
If indemnity satisfactory to the trustee is provided, the holders of a majority in principal amount of the Notes may, with respect to
the Notes, direct in writing the time, method and place of conducting any lawsuit or other formal legal action seeking any remedy available
to the trustee. The trustee may refuse to follow those directions in certain circumstances. No delay or omission in exercising any right
or remedy will be treated as a waiver of the right, remedy or event of default.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Before you are allowed to bypass the trustee
and bring a lawsuit or other formal legal action or take other steps to enforce your rights or protect your interests relating to the
Notes, the following must occur:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>You must give the trustee written notice that an event of default has occurred and remains uncured;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>The holders of at least 25% in principal amount of the outstanding Notes must make a written request that the trustee take action
because of the default and must offer the trustee indemnity reasonably satisfactory to it against the cost and other liabilities of taking
that action;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>The trustee must not have taken action for 60 days after receipt of the above notice and offer of indemnity; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Holders of a majority in principal amount of the Notes must not have given the trustee a direction inconsistent with the above notice.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">However, you are entitled at any time to bring
a lawsuit for the payment of money due on your Notes on or after the due date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Defeasance</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Full Defeasance</I>. If there is a change
in federal tax law, as described below, we can legally release ourselves and any domestic Subsidiary that guarantees our obligations pursuant
to the terms of the Indenture from any payment or other obligations on the Notes, called &ldquo;full defeasance,&rdquo; if we put in place
the following other arrangements for you to be repaid:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>We must deposit in trust for your benefit and the benefit of all other registered holders of the Notes a combination of money and
U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal and any other payments
on the Notes on their various due dates including, possibly, their earliest redemption date.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>In order for us to effect a full defeasance, we must deliver to the trustee a legal opinion confirming that you will not recognize
income, gain or loss for U.S. federal income tax purposes as a result of the defeasance and that you will not be taxed on the Notes any
differently than if the defeasance had not occurred.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 23 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If we accomplish full defeasance, as described
above, you would have to rely solely on the trust deposit for repayment on the Notes. You could not look to us for repayment in the unlikely
event of any shortfall. Conversely, the trust deposit would most likely be protected from claims of our lenders and other creditors if
we ever become bankrupt or insolvent.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Covenant Defeasance</I>. We can make the
same type of deposit described above and be released and cause any domestic Subsidiary that guarantees our obligations pursuant to the
terms of the Indenture to be released from the restrictive covenants in the Notes, if any. This is called &ldquo;covenant defeasance.&rdquo;
In that event, you would lose the protection of those restrictive covenants but would gain the protection of having money and securities
set aside in trust to repay the Notes. In order to achieve covenant defeasance, we must do the following:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>We must deposit in trust for your benefit and the benefit of all other registered holders of the Notes a combination of money and
U.S. government or U.S. government agency notes or bonds that will generate enough cash to make interest, principal and any other payments
on the Notes on their various due dates.</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>We must deliver to the trustee a legal opinion confirming that under current U.S. federal income tax law you will not recognize income,
gain or loss for U.S. federal income tax purposes as a result of the covenant defeasance and that you will not be taxed on the Notes any
differently than if the covenant defeasance had not occurred.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If we accomplish covenant defeasance, the following
provisions of the Indenture and the Notes would no longer apply unless otherwise specified:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>any promises of any domestic Subsidiary that guarantees our obligations pursuant to the terms of the Indenture relating to its guarantees,
the conduct of its business and any other covenants applicable to the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>our promises regarding conduct of our business and other matters and any other covenants applicable to the Notes; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>the definition of an event of default as a breach of such covenants.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If we accomplish covenant defeasance, you can
still look to us and any domestic Subsidiary that guarantees our obligations pursuant to the terms of the Indenture for repayment of the
Notes if there were a shortfall in the trust deposit. In fact, if one of the remaining events of default occurred (such as our bankruptcy)
and the Notes become immediately due and payable, there may be such a shortfall. Depending on the event causing the default, of course,
you may not be able to obtain payment of the shortfall.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In order to exercise either full defeasance
or covenant defeasance, we must comply with certain conditions, and no event or condition can exist that would prevent us and any domestic
Subsidiary that guarantees our obligations pursuant to the terms of the Indenture from making payments of principal, premium, and interest,
if any, on the Notes on the date the irrevocable deposit is made or at any time during the period ending on the 91st day after the deposit
date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Notices</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">With respect to the Notes, we and the trustee
will send notices regarding the Notes only to registered holders, using their addresses as listed in the list of registered holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Future Subsidiary Guarantors</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes do not currently benefit from any
guarantees from any of Quest Diagnostics&rsquo; subsidiaries. To the extent the Indenture governing the existing debt securities requires
any domestic Subsidiary of Quest Diagnostics to guarantee Quest Diagnostics&rsquo; existing debt securities issued under the Indenture,
any such Subsidiary will be required to guarantee the Notes in a substantially consistent manner for so long as such Subsidiary guarantees
such existing debt securities.</P>


<!-- Field: Page; Sequence: 24 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Global Notes: Book-Entry System</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B><I>Global Notes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes will be represented by one or more
fully registered global notes, without interest coupons and will be deposited upon issuance with the trustee as custodian for The Depository
Trust Company, New York, New York (&ldquo;DTC&rdquo;), and registered in the name of DTC or its nominee, in each case, for credit to an
account of a direct or indirect participant as described below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Except as set forth below, the global notes
may be transferred, in whole and not in part, only to another nominee of DTC or to a successor of DTC or its nominee. Beneficial interests
in the global notes may not be exchanged for definitive notes in registered certificated form (&ldquo;certificated notes&rdquo;) except
in the limited circumstances described below. See &ldquo;&mdash;Certain Book-Entry Procedures for the Global Notes.&rdquo;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Except in the limited circumstances described
below, owners of beneficial interests in the global notes will not be entitled to receive physical delivery of notes in certificated form.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Transfers of beneficial interests in the global
notes are subject to the applicable rules and procedures of DTC and its direct or indirect participants, which may change.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Notes may be presented for registration
of transfer and exchange at the offices of the trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B><I>Certain Book-Entry Procedures for the Global Notes</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">All interests in the global notes will be subject
to the operations and procedures of DTC, Euroclear and Clearstream Luxembourg. The descriptions of the operations and procedures of DTC,
Euroclear and Clearstream Luxembourg set forth below are provided solely as a matter of convenience. These operations and procedures are
solely within the control of the respective settlement systems and are subject to change by them from time to time. We obtained the information
in this section and elsewhere in this prospectus supplement concerning DTC, Euroclear and Clearstream Luxembourg and their respective
book-entry systems from sources that we believe are reliable, but we take no responsibility for the accuracy of any of this information,
and investors are urged to contact the relevant system or its participants directly to discuss these matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>DTC</I>. DTC has advised us that it is:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a limited-purpose trust company organized under the laws of the State of New York;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a &#147;banking organization&#148; within the meaning of the New York State Banking Law;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a member of the Federal Reserve System;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a &#147;clearing corporation&#148; within the meaning of the New York Uniform Commercial Code, as amended; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a &#147;clearing agency&#148; registered pursuant to Section 17A of the Exchange Act.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">DTC was created to hold securities for its participants
(collectively, the &ldquo;participants&rdquo;) and to facilitate the clearance and settlement of securities transactions between its participants
through electronic book-entry changes to the accounts of its participants, thereby eliminating the need for physical transfer and delivery
of certificates. DTC&rsquo;s participants include securities brokers and dealers (including some or all of the underwriters), banks and
trust companies, clearing corporations and certain other organizations. Indirect access to DTC&rsquo;s system is also available to other
entities such as Clearstream Luxembourg, Euroclear, banks, brokers, dealers and trust companies (collectively, the &ldquo;indirect participants&rdquo;)
that clear through or maintain a custodial relationship with a participant, either directly or indirectly. Investors who are not participants
may beneficially own securities held by or on behalf of DTC only through participants or indirect participants in DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Clearstream Luxembourg</I>. Clearstream Luxembourg
is incorporated under the laws of Luxembourg as a professional depositary. Clearstream Luxembourg holds securities for its participating
organizations (&ldquo;Clearstream Luxembourg Participants&rdquo;) and facilitates the clearance and settlement of securities transactions
between Clearstream Luxembourg Participants through electronic book-entry changes in accounts of Clearstream Luxembourg Participants,
thereby eliminating the need for physical movement of certificates.</P>


<!-- Field: Page; Sequence: 25 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Clearstream Luxembourg provides Clearstream Luxembourg Participants
with, among other things, services for safekeeping, administration, clearance and establishment of internationally traded securities and
securities lending and borrowing. Clearstream Luxembourg interfaces with domestic markets in several countries. As a professional depositary,
Clearstream Luxembourg is subject to regulation by the Luxembourg Monetary Institute. Clearstream Luxembourg Participants are recognized
financial institutions around the world, including underwriters, securities brokers and dealers, banks, trust companies, clearing corporations
and certain other organizations, and may include the underwriters. Indirect access to Clearstream Luxembourg is also available to others,
such as banks, brokers, dealers and trust companies that clear through or maintain a custodial relationship with a Clearstream Luxembourg
Participant either directly or indirectly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Distributions with respect to Notes held beneficially
through Clearstream Luxembourg will be credited to cash accounts of Clearstream Luxembourg Participants in accordance with its rules and
procedures to the extent received by the U.S. depositary for Clearstream Luxembourg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Euroclear</I>. Euroclear was created in 1968
to hold securities for participants of Euroclear (&ldquo;Euroclear Participants&rdquo;) and to clear and settle transactions between Euroclear
Participants through simultaneous electronic book-entry delivery against payment, thereby eliminating the need for physical movement of
certificates and any risk from lack of simultaneous transfers of securities and cash. Euroclear includes various other services, including
securities lending and borrowing and interfaces with domestic markets in several markets in several countries. Euroclear is operated by
Euroclear Bank S.A./N.V. (the &ldquo;Euroclear Operator&rdquo;), under contract with Euroclear Clearance Systems S.C., a Belgian cooperative
corporation (the &ldquo;Cooperative&rdquo;). All operations are conducted by the Euroclear Operator, and all Euroclear securities clearance
accounts and Euroclear cash accounts are accounts with the Euroclear Operator, not the Cooperative. The Cooperative establishes policy
for Euroclear on behalf of Euroclear Participants. Euroclear Participants include banks (including central banks), securities brokers
and dealers and other professional financial intermediaries and may include the underwriters. Indirect access to Euroclear is also available
to other firms that clear through or maintain a custodial relationship with a Euroclear Participant, either directly or indirectly.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Euroclear Operator is regulated and examined
by the Belgian Banking Commission. Distributions of principal and interest with respect to Notes held through Euroclear or Clearstream
Luxembourg will be credited to the cash accounts of Euroclear or Clearstream Luxembourg participants in accordance with the relevant system&rsquo;s
rules and procedures, to the extent received by such system&rsquo;s depositary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Links have been established among DTC, Clearstream
Luxembourg and Euroclear to facilitate the initial issuance of the Notes and cross-market transfers of the Notes associated with secondary
market trading. DTC will be linked indirectly to Clearstream Luxembourg and Euroclear through the DTC accounts of their respective U.S.
depositaries.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Book-Entry Procedures</I>. We expect that,
pursuant to procedures established by DTC:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>upon deposit of each global note, DTC will credit, on its book-entry registration and transfer system, the accounts of participants
designated by the underwriters with an interest in that global note; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>ownership of beneficial interests in the global notes will be shown on, and the transfer of ownership interests in the global notes
will be effected only through, records maintained by DTC (with respect to the interests of participants) and by participants and indirect
participants (with respect to the interests of persons other than participants).</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The laws of some jurisdictions may require that
some purchasers of Notes take physical delivery of those Notes in definitive form. Accordingly, the ability to transfer beneficial interests
in notes represented by a global note to those persons may be limited. In addition, because DTC can act only on behalf of its participants,
who in turn act on behalf of persons who hold interests through participants, the ability of a person holding a beneficial interest in
a global note to pledge or transfer that interest to persons or entities that do not participate in DTC&rsquo;s system, or to otherwise
take actions in respect of that interest, may be affected by the lack of a physical note in respect of that interest.</P>


<!-- Field: Page; Sequence: 26 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">So long as DTC or its nominee is the registered
owner of a global note, DTC or that nominee, as the case may be, will be considered the sole legal owner or holder of the notes represented
by that global note for all purposes of the Notes and the Indenture. Except as provided below, owners of beneficial interests in a global
note (1) will not be entitled to have the Notes represented by that global note registered in their names, (2) will not receive or be
entitled to receive physical delivery of certificated notes, and (3) will not be considered the owners or holders of the Notes represented
by that beneficial interest under the Indenture for any purpose, including with respect to the giving of any direction, instruction or
approval to the trustee. Accordingly, each holder owning a beneficial interest in a global note must rely on the procedures of DTC and,
if that holder is not a participant or an indirect participant, on the procedures of the participant through which that holder owns its
interest, to exercise any rights of a holder of Notes under the Indenture or that global note. We understand that under existing industry
practice, in the event that we request any action of holders of notes, or a holder that is an owner of a beneficial interest in a global
note desires to take any action that DTC, as the holder of that global note, is entitled to take, DTC would authorize the participants
to take that action and the participants would authorize holders owning through those participants to take that action or would otherwise
act upon the instruction of those holders. Neither we nor the Trustee will have any responsibility or liability for any aspect of the
records relating to or payments made on account of notes by DTC, or for maintaining, supervising or reviewing any records of DTC relating
to the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Payments with respect to the principal of and
interest on a global note will be payable by the trustee to or at the direction of DTC or its nominee in its capacity as the registered
holder of the global note under the Indenture. Under the terms of the Indenture, we and the trustee may treat the persons in whose names
the Notes, including the global notes, are registered as the owners thereof for the purpose of receiving payment thereon and for any and
all other purposes whatsoever. Accordingly, neither we nor the trustee has or will have any responsibility or liability for the payment
of those amounts to owners of beneficial interests in a global note. Payments by the participants and the indirect participants to the
owners of beneficial interests in a global note will be governed by standing instructions and customary industry practice and will be
the responsibility of the participants and indirect participants and not of DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Transfers between participants in DTC will be
effected in accordance with DTC&rsquo;s procedures, and will be settled in same-day funds. Transfers between participants in Euroclear
or Clearstream Luxembourg will be effected in the ordinary way in accordance with their respective rules and operating procedures.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Cross-market transfers between the participants
in DTC, on the one hand, and Euroclear or Clearstream Luxembourg participants, on the other hand, will be effected through DTC in accordance
with DTC&rsquo;s rules on behalf of Euroclear or Clearstream Luxembourg, as the case may be, by its respective depositary. However, those
cross-market transactions will require delivery of instructions to Euroclear or Clearstream Luxembourg, as the case may be, by the counterparty
in that system in accordance with the rules and procedures and within the established deadlines (Brussels time) of that system. Euroclear
or Clearstream Luxembourg, as the case may be, will, if the transaction meets its settlement requirements, deliver instructions to its
respective depositary to take action to effect final settlement on its behalf by delivering or receiving interests in the relevant global
notes in DTC, and making or receiving payment in accordance with normal procedures for same-day funds settlement applicable to DTC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Euroclear participants and Clearstream Luxembourg
participants may not deliver instructions directly to the depositaries for Euroclear or Clearstream Luxembourg.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Although we understand that DTC, Euroclear and
Clearstream Luxembourg have agreed to the foregoing procedures to facilitate transfers of interests in the global notes among participants
in DTC, Euroclear and Clearstream Luxembourg, they are under no obligation to perform or to continue to perform those procedures, and
those procedures may be discontinued at any time. Neither we nor the trustee will have any responsibility for the performance by DTC,
Euroclear or Clearstream Luxembourg or their respective participants or indirect participants of their respective obligations under the
rules and procedures governing their operations.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B><I>Same-Day Settlement and Payment</I></B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We will make payments in respect of the Notes
represented by the global notes (including principal and interest) by wire transfer of immediately available funds to the accounts specified
by the global note holder. We will make all payments of principal and interest with respect to certificated notes by wire transfer of
immediately available funds to the accounts specified by the holders of the certificated notes or, if no such account is specified, by
mailing a check to each such holder&rsquo;s registered address. The Notes represented by the global notes are expected to trade in DTC&rsquo;s
Same-Day Funds Settlement System.</P>


<!-- Field: Page; Sequence: 27 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Because of time zone differences, the securities
account of a Euroclear or Clearstream Luxembourg participant purchasing an interest in a global note from a participant in DTC will be
credited, and any such crediting will be reported to the relevant Euroclear or Clearstream Luxembourg participant, during the securities
settlement processing day (which must be a business day for Euroclear and Clearstream Luxembourg) immediately following the settlement
date of DTC. DTC has advised us that cash received in Euroclear or Clearstream Luxembourg as a result of sales of interests in a global
note by or through a Euroclear or Clearstream Luxembourg participant to a participant in DTC will be received with value on the settlement
date of DTC but will be available in the relevant Euroclear or Clearstream Luxembourg cash account only as of the business day for Euroclear
or Clearstream Luxembourg following DTC&rsquo;s settlement date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">None of Quest Diagnostics, any underwriter or
agent, the trustee or any applicable paying agent will have any responsibility or liability for any aspect of the records relating to
or payments made on account of beneficial interests in a global note, or for maintaining, supervising or reviewing any records.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Modification or Waiver</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">There are three types of changes we can make
to the Indenture and the Notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Changes Requiring Your Approval</I>. First,
there are changes that cannot be made to your Notes without your specific approval. Following is a list of those types of changes:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>changing the stated maturity of the principal of or interest on the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>reducing any amounts due on the Notes or payable upon acceleration of the maturity of the security following a default;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>adversely affecting any right of repayment at the holder&#146;s option;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>changing the place (except as otherwise described in this prospectus supplement) or currency of payment on the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>impairing your right to sue for payment or to convert or exchange Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>modifying the Notes to subordinate the Notes to other indebtedness;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>reducing the percentage of holders of Notes whose consent is needed to modify or amend the Indenture;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>reducing the percentage of holders of Notes whose consent is needed to waive compliance with certain provisions of the Indenture or
to waive certain defaults;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>reducing the requirements for quorum or voting with respect to the Notes;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>modifying any other aspect of the provisions of the Indenture dealing with modification and waiver except to increase the voting requirements;
and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>change in any of our obligations to pay additional amounts to holders with respect to taxes imposed on such holders in certain circumstances.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Changes Requiring a Majority Vote</I>. The
second type of change to the Indenture and the outstanding Notes is the kind that requires a vote in favor by holders of outstanding Notes
owning a majority of the principal amount of Notes. Most changes fall into this category, except for clarifying changes and certain other
changes that would not adversely affect holders of the outstanding Notes in any material respect. The same vote would be required for
us and any domestic Subsidiary that guarantees our obligations pursuant to the terms of the Indenture to obtain a waiver of all or part
of certain covenants in the Indenture, or a waiver of a past default. However, we and any domestic Subsidiary that guarantees our obligations
pursuant to the terms of the Indenture cannot obtain a waiver of a payment default or any other aspect of the Indenture or the outstanding
Notes listed in the category described previously under &ldquo;&mdash;Changes Requiring Your Approval&rdquo; unless we and such Subsidiary
obtain your individual consent to the waiver.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in"><I>Changes Not Requiring Approval</I>. The third
type of change does not require any vote by holders of outstanding Notes. This type is limited to clarifications, curing ambiguities,
defects or inconsistencies and certain other changes that would not adversely affect holders of the outstanding Notes in any material
respect. Qualifying or maintaining the qualification of the Indenture under the Trust Indenture Act does not require any vote by holders
of Notes.</P>


<!-- Field: Page; Sequence: 28 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Satisfaction and Discharge</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Indenture will cease to be of further effect,
and we and our Subsidiaries that have guaranteed our obligations pursuant to the terms of the Indenture, if any, will be deemed to have
satisfied and discharged the Indenture with respect to the Notes, when the following conditions have been satisfied:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>all Notes not previously delivered to the trustee for cancellation have become due and payable or will become due and payable at their
stated maturity or on a redemption date within one year;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>we deposit with the trustee, in trust, funds sufficient to pay the entire indebtedness on the Notes that had not been previously delivered
for cancellation, for the principal and interest to the date of the deposit (for Notes that have become due and payable) or to the stated
maturity or the redemption date, as the case may be (for Notes that have not become due and payable);</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>we have paid or caused to be paid all other sums payable under the Indenture; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>we have delivered to the trustee an Officer&#146;s Certificate and opinion of counsel, each stating that all these conditions have
been complied with.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We will remain obligated to provide for registration
of transfer and exchange and to provide notices of redemption.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>The Trustee</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The trustee will be The Bank of New York Mellon
(formerly, The Bank of New York). The Bank of New York Mellon also will be the initial paying agent and registrar for the Notes. The Bank
of New York Mellon is also the trustee and note registrar for our 4.25% senior notes due 2024, our 3.50% senior notes due 2025, our 3.45%
senior notes due 2026, our 4.20% senior notes due 2029, our 2.95% senior notes due 2030, our 2.80% Senior Notes due June 2031, our 6.95%
senior notes due 2037, our 5.75% senior notes due 2040 and our 4.70% senior notes due 2045.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Indenture provides that, except during the
continuance of an event of default under the Indenture, the trustee under the Indenture will perform only such duties as are specifically
set forth in the Indenture. Under the Indenture, the holders of a majority in outstanding principal amount of the Notes will have the
right to direct the time, method and place of conducting any proceeding or exercising any remedy available to the trustee under the Indenture,
subject to certain exceptions. The trustee shall be under no obligation to exercise any of the rights or powers vested in it by the Indenture
at the request or direction of any of the Holders pursuant to the Indenture, unless such Holders shall have offered to the trustee security
or indemnity satisfactory to the trustee against the costs, expenses and liabilities which might be incurred by it in compliance with
such request or direction. If an event of default has occurred and is continuing, the trustee under the Indenture will exercise such rights
and powers vested in it under the Indenture and use the same degree of care and skill in its exercise as a prudent person would exercise
under the circumstances in the conduct of such person&rsquo;s own affairs.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Indenture and provisions of the Trust Indenture
Act incorporated by reference in the Indenture contain limitations on the rights of the trustee under such Indenture, should it become
a creditor of our company, to obtain payment of claims in certain cases or to realize on certain property received by it in respect of
any such claims, as security or otherwise. The trustee under the Indenture is permitted to engage in other transactions. However, if the
trustee under the Indenture acquires any prohibited conflicting interest, it must eliminate the conflict or resign.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The trustee may resign or be removed and a successor
trustee may be appointed.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Governing Law</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Indenture and the Notes will be governed
by, and construed in accordance with, the laws of the State of New York without application of principles of conflicts of law thereunder.</P>


<!-- Field: Page; Sequence: 29 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Definitions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following definitions are applicable to
this Description of Notes:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Acquired Indebtedness&rdquo; means Indebtedness
of a Person (1) existing at the time such Person becomes a Restricted Subsidiary or (2) assumed in connection with the acquisition of
assets by such Person, in each case, other than Indebtedness incurred in connection with, or in contemplation of, such Person becoming
a Restricted Subsidiary or such acquisition, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Attributable Debt&rdquo; means, with
respect to a Sale and Leaseback Transaction, an amount equal to the lesser of: (1) the fair market value of the property (as determined
in good faith by our board of directors); and (2) the present value of the total net amount of rent payments to be made under the lease
during its remaining term, discounted at the rate of interest set forth or implicit in the terms of the lease, compounded semiannually.
The calculation of the present value of the total net amount of rent payments is subject to adjustments specified in the Indenture.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Capitalized Lease&rdquo; means any obligation
of a Person to pay rent or other amounts incurred with respect to real property or equipment acquired or leased by such Person and used
in its business that is required to be recorded as a capital lease in accordance with generally accepted accounting principles.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Consolidated Total Assets&rdquo; means,
with respect to any Person as of any date, the amount of total assets as shown on the consolidated balance sheet of such Person for the
most recent fiscal quarter for which financial statements have been filed with the Securities and Exchange Commission, prepared in accordance
with accounting principles generally accepted in the United States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Existing Receivables Credit Facility&rdquo;
means the receivables-backed financing transaction pursuant to (1) the Fourth Amended and Restated Receivables Sale Agreement, dated as
of October 28, 2015 between Quest Diagnostics and each of its direct and indirect wholly owned Subsidiaries that is a seller thereunder,
and Quest Diagnostics Receivables Inc., as the buyer, as amended (2) the Sixth Amended and Restated Credit and Security Agreement, dated
as of October 27, 2017, among Quest Diagnostics Receivables Inc., as borrower, Quest Diagnostics, as initial servicer, each of the lenders
from time to time party thereto, and The Bank of Tokyo-Mitsubishi UFJ, Ltd., New York Branch, as administrative agent, as amended and
(3) the various related ancillary documents.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Indebtedness&rdquo; of any Person means,
without duplication (1) any obligation of such Person for money borrowed, (2) any obligation of such Person evidenced by bonds, debentures,
notes or other similar instruments, (3) any reimbursement obligation of such Person in respect of letters of credit or other similar instruments
which support financial obligations which would otherwise become Indebtedness, and (4) any obligation of such Person under Capitalized
Leases; <I>provided</I>, <I>however</I>, that &ldquo;Indebtedness&rdquo; of such Person shall not include any obligation of such Person
to any Subsidiary of such Person or to any Person with respect to which such Person is a Subsidiary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Lien&rdquo; means any pledge, mortgage,
lien, encumbrance or other security interest.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Officer&rsquo;s Certificate&rdquo; means
a certificate signed by any Officer of Quest Diagnostics or any domestic Subsidiary that guarantees the obligations of Quest Diagnostics
pursuant to the terms of the Indenture, as the case may be, in his or her capacity as such Officer and delivered to the trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Permitted Acquired Indebtedness&rdquo;
means any Acquired Indebtedness that remains outstanding following the expiration of a good faith offer by Quest Diagnostics or the Subsidiary
of Quest Diagnostics obligated under such Acquired Indebtedness to acquire such Acquired Indebtedness, including, without limitation,
an offer to exchange such Acquired Indebtedness for debt securities of Quest Diagnostics, on terms, which in the opinion of an independent
investment banking firm of national reputation and standing, are consistent with market practices in existence at the time for offers
of a similar nature; <I>provided</I> that the initial expiration date of any such offer shall be not later than the expiration of the
270-day period referred to in the first paragraph of the &ldquo;&mdash;Limitation on Subsidiary Indebtedness and Preferred Stock&rdquo;
covenant<I>; provided further</I> that the amount of Acquired Indebtedness that shall constitute &ldquo;Permitted Acquired Indebtedness&rdquo;
shall only be equal to the amount of Acquired Indebtedness that Quest Diagnostics or such Subsidiary has made an offer to acquire in accordance
with the foregoing.</P>


<!-- Field: Page; Sequence: 30 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Person&rdquo; means any individual, corporation,
limited liability company, partnership, joint venture, association, joint stock company, trust, unincorporated organization or government
or any agency or political subdivision thereof or other similar entity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Preferred Stock&rdquo; means, with respect
to any Person, any and all shares of preferred stock (however designated) issued by such Person, that is entitled to preference or priority
over one or more series or classes of capital stock issued by such Person upon any distribution of such Person&rsquo;s property and assets,
whether by dividend or on liquidation, whether now outstanding, or issued after the date that the Notes are issued.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Principal Property&rdquo; means any real
property and any related buildings, fixtures or other improvements located in the United States owned by Quest Diagnostics or its Subsidiaries
(1) on or in which one of its 30 largest domestic clinical laboratories conducts operations, as determined by net revenues for the four
most recent fiscal quarters for which financial statements have been filed with the Securities and Exchange Commission, or (2) the net
book value of which at the time of the determination exceeds 1% of the Consolidated Total Assets of Quest Diagnostics.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Receivables Credit Facility&rdquo; means
any receivables-backed financing transaction including the Existing Receivables Credit Facility, in each case as such transaction may
be amended or otherwise modified from time to time or refinanced or replaced with respect to all or any portion of the indebtedness under
such transaction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Restricted Subsidiary&rdquo; means any
Subsidiary of Quest Diagnostics that owns a Principal Property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Sale and Leaseback Transaction&rdquo;
means any arrangement with any person providing for the leasing by Quest Diagnostics or any Restricted Subsidiary of any Principal Property
that has been or is to be sold or transferred by Quest Diagnostics or any Restricted Subsidiary to such person, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&ldquo;Subsidiary&rdquo; of any Person means
(1) a corporation, a majority of the outstanding voting stock of which is, at the time, directly or indirectly, owned by such Person by
one or more Subsidiaries of such Person, or by such Person and one or more Subsidiaries thereof or (2) any other Person (other than a
corporation), including, without limitation, a partnership or joint venture, in which such Person, one or more Subsidiaries thereof or
such Person and one or more Subsidiaries thereof, directly or indirectly, at the date of determination thereof, has at least majority
ownership interest entitled to vote in the election of directors, managers or trustees thereof (or other Person performing similar functions).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 31 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><B><A NAME="a_007" TITLE="incometaxconsiderations"></A>UNITED STATES
FEDERAL INCOME TAX CONSIDERATIONS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following discussion is a summary of the
material U.S. federal income tax consequences relevant to the purchase, ownership and disposition of the notes, but does not purport to
be a complete analysis of all potential tax effects. The discussion is based upon the Internal Revenue Code of 1986, as amended (the &ldquo;Code&rdquo;),
U.S. Treasury regulations issued thereunder, Internal Revenue Service (&ldquo;IRS&rdquo;) rulings and pronouncements and judicial decisions
now in effect, all of which are subject to change at any time. Any such change may be applied retroactively in a manner that could adversely
affect a beneficial owner of the notes. This discussion does not address alternative minimum tax consequences, U.S. federal estate or
gift tax laws, the Medicare tax on net investment income or all of the U.S. federal income tax consequences that may be relevant to a
beneficial owner of the notes in light of such beneficial owner&rsquo;s particular circumstances or to beneficial owners of the notes
subject to special rules, such as financial institutions, U.S. expatriates, insurance companies, dealers in securities or foreign currencies,
traders in securities, &ldquo;U.S. Holders&rdquo; (as defined below) whose functional currency is not the U.S. dollar, partnerships and
other pass-through entities and their beneficial owners, tax-exempt organizations or accounts and persons holding the notes as part of
a &ldquo;straddle,&rdquo; &ldquo;hedge,&rdquo; &ldquo;conversion transaction&rdquo; or other integrated transaction. In addition, this
discussion is limited to beneficial owners of notes that purchase notes for cash in this offering at a price equal to their &ldquo;issue
price&rdquo; within the meaning of Section 1273 of the Code (i.e. the first price at which a substantial amount of the notes is sold to
the public for cash), and that hold the notes as &ldquo;capital assets&rdquo; within the meaning of Section 1221 of the Code (generally,
property held for investment). Moreover, the effect of any applicable state, local or foreign tax laws, and any part of U.S. federal tax
law other than law pertaining to income taxation, is not discussed in this summary.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">As used in this prospectus supplement, &ldquo;U.S.
Holder&rdquo; means a beneficial owner of the notes that is for U.S. federal income tax purposes:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>an individual who is a citizen or resident of the United States;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a corporation (or other entity taxable as a corporation) created or organized in or under the laws of the United States, any state
thereof or the District of Columbia;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>an estate, the income of which is subject to U.S. federal income tax regardless of its source; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>a trust, if a (i) U.S. court can exercise primary supervision over the administration of the trust and one or more &#147;United States
persons&#148; within the meaning of Section 7701(a)(30) of the Code can control all substantial trust decisions, or (ii) if the trust
was in existence on August 20, 1996 and has elected to continue to be treated as a U.S. person.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">A &ldquo;non-U.S. Holder&rdquo; is a beneficial
owner of notes that is neither a U.S. Holder nor a partnership (or other entity or arrangement treated as a partnership) for U.S. federal
income tax purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If a beneficial owner of the notes is a partnership
or other entity or arrangement treated as a partnership for U.S. federal income tax purposes, the tax treatment of the partnership and
each partner in such partnership generally will depend on the activities of the partnership, the status of the partner and certain determinations
made at the partner level. Partnerships that hold notes, and partners in such partnerships, should consult their own tax advisors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Prospective investors should consult their own
tax advisors with regard to the application of the tax consequences discussed below to their particular situations as well as the application
of any state, local, foreign or other tax laws, including gift and estate tax laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>U.S. Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in"><I>Payment of Stated Interest</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Payments of stated interest on the notes generally
will be taxable to a U.S. Holder as ordinary income at the time that such payments are received or accrued, in accordance with such U.S.
Holder&rsquo;s regular method of accounting for U.S. federal income tax purposes.</P>


<!-- Field: Page; Sequence: 32 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in"><I>Sale or Other Taxable Disposition of the Notes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">A U.S. Holder will recognize gain or loss on
the sale, exchange, redemption, retirement or other taxable disposition of a note in an amount equal to the difference between the amount
realized upon the disposition (less any portion allocable to any accrued and unpaid stated interest, which will be taxable as ordinary
interest income to the extent not previously included in gross income) and the U.S. Holder&rsquo;s tax basis in the note. A U.S. Holder&rsquo;s
tax basis in a note generally will be the price such U.S. Holder paid for the note. Such gain or loss generally will be a capital gain
or loss, and will be a long-term capital gain or loss if the U.S. Holder has held the note for more than one year at the time of the disposition.
Non-corporate U.S. Holders may be eligible for reduced rates of U.S. federal income tax on long-term capital gains. The deductibility
of capital losses is subject to limitations under the Code.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in"><I>Backup Withholding and Information Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In general, information reporting requirements
will apply to payments of interest on the notes and to the proceeds of the sale or other disposition (including a retirement or redemption)
of a note paid to a U.S. Holder unless such U.S. Holder is an exempt recipient and, when required, provides evidence of such exemption.
In addition, a U.S. Holder may be subject to backup withholding on such payments. Certain U.S. Holders (including, among others, corporations
and certain tax-exempt organizations) generally are exempt from backup withholding, but may be required to certify to their exempt status.
A non-exempt U.S. Holder will be subject to backup withholding if such U.S. Holder:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>fails to furnish its taxpayer identification number (&#147;TIN&#148;), which, for an individual, ordinarily is his or her social security
number;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>furnishes an incorrect TIN;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>is notified by the IRS that the U.S. Holder has failed to properly report payments of interest or dividends; or</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>fails to certify, under penalties of perjury, that the U.S. Holder is a U.S. person, has furnished a correct TIN and that the IRS
has not notified the U.S. Holder that it is subject to backup withholding.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">U.S. Holders should consult their own tax advisors
regarding their qualification for an exemption from backup withholding and the procedures for obtaining such an exemption, if applicable.
The backup withholding tax is not an additional tax and U.S. Holders may use amounts withheld as a credit against their U.S. federal income
tax liability or such amounts may be refunded to the U.S. Holder so long as the requisite information is timely furnished to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Non-U.S. Holders</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in"><I>Payment of Stated Interest</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Subject to the discussions below regarding backup
withholding and FATCA (as defined below), interest paid to a non-U.S. Holder generally will not be subject to U.S. federal income tax
or U.S. federal withholding tax of 30% (or, if applicable, a lower treaty rate), provided:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>such non-U.S. Holder does not directly or indirectly, actually or constructively, own 10% or more of the total combined voting power
of all of our classes of stock;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>such non-U.S. Holder is not a controlled foreign corporation that is related to us through sufficient direct or indirect stock ownership;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>such interest is not effectively connected with a trade or business conducted by the non-U.S. Holder within the United States; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>(1) the non-U.S. Holder provides the applicable withholding agent with a properly completed IRS Form W-8BEN or W-8BEN-E (or other
applicable form), which includes its name and address and a certification, under penalties of perjury, that the non-U.S. Holder is not
a &#147;United States person&#148; within the meaning of the Code, or (2) a securities clearing organization, bank or other financial
institution that holds customers&#146; securities in the ordinary course of its trade or business and holds the notes on behalf of the
non-U.S. Holder certifies to the applicable withholding agent under penalties of perjury that it, or the financial institution between
it and the non-U.S. Holder, has received from the non-U.S. Holder a properly completed IRS Form W-8BEN or W-8BEN-E (or other applicable
form), which includes a statement, under penalties of perjury, that such non-U.S. Holder is not a &#147;United States person&#148; and
provides the applicable withholding agent with a copy of this statement.</TD></TR></TABLE>


<!-- Field: Page; Sequence: 33 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If a non-U.S. Holder cannot satisfy the requirements
described above, payments of interest made to the non-U.S. Holder will be subject to the 30% U.S. federal withholding tax, unless the
non-U.S. Holder provides the applicable withholding agent with a properly executed (1) IRS Form W-8BEN or W-8BEN-E (or other applicable
form) claiming an exemption from or reduction in withholding under the benefit of an applicable tax treaty or (2) IRS Form W-8ECI (or
other applicable form) stating that interest paid on the notes is not subject to withholding tax because it is effectively connected with
such non-U.S. Holder&rsquo;s conduct of a trade or business in the United States, in which case the non-U.S. Holder generally will be
subject to tax on a net basis on payments of interest made to the non-U.S. Holder in the same manner as a U.S. Holder, as described below
in the second paragraph under &ldquo;&mdash;Sale or Other Taxable Disposition of the Notes.&rdquo; Prospective investors should consult
their tax advisors regarding the certification requirements for non-U.S. Holders.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in"><I>Sale or Other Taxable Disposition of the Notes</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Subject to the discussion below regarding backup
withholding, a non-U.S. Holder generally will not be subject to U.S. federal income tax or withholding tax on gain and any accrued interest
recognized on the sale, exchange, redemption, retirement or other disposition of a note unless (1) such gain is effectively connected
with a trade or business conducted by the non-U.S. Holder within the United States (and, if required by an applicable income tax treaty,
is attributable to a U.S. &ldquo;permanent establishment&rdquo; maintained by the non-U.S. Holder), (2) such non-U.S. Holder is an individual
who was present in the United States for 183 days or more in the taxable year of the disposition and certain other conditions are met
(in which case, except as otherwise provided by an applicable income tax treaty, such gain, which may be offset by U.S. source capital
losses, generally will be subject to a flat 30% U.S. federal income tax, even though the non-U.S. Holder is not considered a resident
alien under the Code) or (3) in the case of accrued interest, such accrued interest does not qualify for the exemption from U.S. federal
income tax and U.S. federal withholding tax discussed above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If interest on the notes or gain from a disposition
of the notes is effectively connected with a non-U.S. Holder&rsquo;s conduct of a U.S. trade or business (and, if required by an applicable
income tax treaty, is attributable to a U.S. &ldquo;permanent establishment&rdquo; maintained by the non-U.S. Holder), the non-U.S. Holder
generally will be subject to U.S. federal income tax on the interest or gain on a net basis in the same manner as U.S. Holders. For effectively-connected
interest, the 30% withholding tax described above will not apply (assuming an appropriate certification is timely provided by the non-U.S.
Holder). A foreign corporation that is a non-U.S. Holder of a note also may be subject to a branch profits tax equal to 30% of its effectively
connected earnings and profits for the taxable year, subject to certain adjustments, unless it qualifies for a lower rate under an applicable
income tax treaty.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in"><I>Backup Withholding and Information Reporting</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Backup withholding and information reporting
generally will not apply to payments to a non-U.S. Holder of a note if the non-U.S. Holder has provided the applicable withholding agent
with the required certification that it is not a U.S. person as described above in &ldquo;&mdash;Payment of Stated Interest,&rdquo; <I>provided</I>
that the applicable withholding agent does not have actual knowledge or reason to know that the non-U.S. Holder is a U.S. person. However,
the applicable withholding agent may be required to report to the IRS and to non-U.S. Holders payments of interest on the notes and the
amount of tax, if any, withheld with respect to those payments. Copies of the information returns reporting such interest payments and
any withholding may also be made available to the tax authorities in the country in which such non-U.S. Holders reside under the provisions
of a treaty or agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">If a non-U.S. Holder sells a note outside the
United States through a non-U.S. office of a non-U.S. broker and the sales proceeds are paid to the non-U.S. Holder outside the United
States, then backup withholding and information reporting generally will not apply to that payment. However, information reporting, but
not backup withholding, will apply to a payment of sales proceeds, even if that payment is made outside the United States, if a non-U.S.
Holder sells a note through a non-U.S. office of a broker with certain U.S. connections, unless such broker has documentary evidence in
its possession of the required certification of the non-U.S. Holder&rsquo;s foreign status as described above and has no knowledge or
reason to know to the contrary, or the non-U.S. Holder otherwise establishes an exemption.</P>


<!-- Field: Page; Sequence: 34 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Payment of the proceeds from a disposition by
a non-U.S. Holder of a note made to or through the U.S. office of a broker generally will be subject to information reporting and backup
withholding unless the non-U.S. Holder certifies that it is not a &ldquo;United States person&rdquo; or otherwise establishes an exemption
from information reporting and backup withholding.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Non-U.S. Holders should consult their own tax
advisors regarding application of backup withholding in their particular circumstance and the availability of any procedure for obtaining
an exemption from backup withholding under current Treasury regulations. Any amounts withheld under the backup withholding rules from
a payment to a non-U.S. Holder will be allowed as a credit against the non-U.S. Holder&rsquo;s U.S. federal income tax liability or such
amounts may be refunded to the non-U.S. Holder, <I>provided</I> the required information is timely furnished to the IRS.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Foreign Account Tax Compliance Act</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The Foreign Account Tax Compliance Act and Treasury
regulations thereunder, commonly referred to as &ldquo;FATCA,&rdquo; impose a U.S. federal withholding tax of 30% on certain types of
payments, including payments of U.S. source interest (such as interest on the notes), made to beneficial owners or intermediaries that
are (i) &ldquo;foreign financial institutions&rdquo; unless they agree to collect and disclose to the IRS information regarding their
direct and indirect U.S. account holders and comply with certain other requirements and (ii) certain non-financial foreign entities unless
they satisfy certain information reporting requirements regarding their direct and indirect U.S. owners. Accordingly, the entity through
which a U.S. Holder or a non-U.S. Holder holds its notes will affect the determination of whether such withholding is required. Foreign
financial institutions located in jurisdictions that have an intergovernmental agreement in place with the United States with respect
to FATCA may be subject to modified rules. You are urged to consult your own tax advisor regarding FATCA and the application of these
requirements to your investment in the notes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 35 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><B><A NAME="a_008" TITLE="underwriting"></A>UNDERWRITING
(CONFLICTS OF INTEREST)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Under the terms and subject to the conditions
contained in an underwriting agreement dated the date of this prospectus supplement, the underwriters named below for whom Goldman Sachs
&amp; Co. LLC, Mizuho Securities USA LLC and Morgan Stanley &amp; Co. LLC are acting as representatives and have severally agreed to purchase,
and we have agreed to sell to them, severally, the principal amount of notes indicated in the table below:</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font-weight: bold">Underwriter</TD><TD STYLE="font-weight: bold; padding-bottom: 1pt">&nbsp;</TD>
    <TD COLSPAN="3" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1pt solid">Principal Amount of Notes</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="width: 70%; text-align: left; padding-left: 5.4pt">Goldman Sachs &amp; Co. LLC</TD><TD STYLE="width: 1%">&nbsp;</TD>
    <TD STYLE="width: 1%; text-align: left">$</TD><TD STYLE="width: 27%; text-align: right">157,500,000</TD><TD STYLE="width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Mizuho Securities USA LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">157,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Morgan Stanley &amp; Co. LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">157,500,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">J.P. Morgan Securities LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">69,375,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Wells Fargo Securities, LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">69,375,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Credit Agricole Securities (USA) Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">28,125,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">MUFG Securities Americas Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">28,125,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">PNC Capital Markets LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">24,375,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">Fifth Third Securities, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">18,750,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">KeyBanc Capital Markets Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">16,875,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="text-align: left; padding-left: 5.4pt">BofA Securities, Inc.</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="text-align: left; padding-left: 5.4pt">BNY Mellon Capital Markets, LLC</TD><TD>&nbsp;</TD>
    <TD STYLE="text-align: left">$</TD><TD STYLE="text-align: right">11,250,000</TD><TD STYLE="text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font-weight: bold; padding-bottom: 2.5pt; padding-left: 5.4pt">Total</TD><TD STYLE="font-weight: bold; padding-bottom: 2.5pt">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: left">$</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">750,000,000</TD><TD STYLE="border-bottom: Black 2.5pt double; font-weight: bold; text-align: right">&nbsp;</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The underwriters are offering the notes subject
to their acceptance of the notes from us and subject to prior sale. The underwriting agreement provides that the obligations of the several
underwriters to pay for and accept delivery of the notes offered by this prospectus supplement are subject to the approval of certain
legal matters by their counsel and to certain other conditions. The underwriters are obligated to take and pay for all the notes offered
by this prospectus supplement if any such notes are taken. The offering of the notes by the underwriters is subject to receipt and acceptance
and subject to the underwriters&rsquo; right to reject any order in whole or in part.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The underwriters initially propose to offer
part of the notes directly to the public at the public offering prices set forth on the cover page of this prospectus supplement and part
to certain dealers at a price that represents a concession not in excess of 0.40% of the principal amount of
the notes. Any such dealers may resell any notes purchased from the underwriters to certain other brokers or dealers at a discount not
to exceed 0.25% of the principal amount of the notes. After the initial offering of the notes, the offering
price and other selling terms may from time to time be varied by the representatives.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The following table shows the per note and total
public offering price, underwriting discount and proceeds before expenses to us:</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 73%; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;</TD>
    <TD STYLE="width: 17%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid"><B>Per Note</B></P></TD>
    <TD STYLE="width: 10%; padding-right: 5.4pt; padding-left: 5.4pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; border-bottom: Black 0.5pt solid"><B>Total</B></P></TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Public offering price<SUP>(1)</SUP></TD>
    <TD STYLE="text-align: right; padding-right: 5.4pt; padding-left: 5.4pt">99.947%</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">$749,602,500</TD></TR>
  <TR STYLE="vertical-align: top; background-color: White">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Underwriting discount </TD>
    <TD STYLE="text-align: right; padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;&nbsp;0.650%</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">&nbsp;&nbsp;&nbsp;&nbsp;$4,875,000</TD></TR>
  <TR STYLE="vertical-align: top; background-color: rgb(204,238,255)">
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">Proceeds, before expenses, to us </TD>
    <TD STYLE="text-align: right; padding-right: 5.4pt; padding-left: 5.4pt">99.297%</TD>
    <TD STYLE="padding-right: 5.4pt; padding-left: 5.4pt">$744,727,500</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 6pt 0; text-indent: 0.75pt"><SUP>(1)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Plus
accrued interest from November 1, 2023, if settlement occurs after that date.</SUP></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The estimated offering expenses payable by us,
exclusive of the underwriting discount, are approximately $2 million.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In order to facilitate the offering of the notes,
the underwriters may engage in transactions that stabilize, maintain or otherwise affect the prices of the notes. Specifically, the underwriters
may over-allot in connection with the offering, creating short positions in the notes for their own account. In addition, to cover over-allotments
or to stabilize the prices of the notes, the underwriters may bid for and purchase notes on the open market. Further, the underwriting
syndicate may reclaim selling concessions allowed to an underwriter or a dealer for distributing the notes in the offering, if the syndicate
repurchases previously distributed notes in transactions to cover syndicate short positions, in stabilization transactions or otherwise.
Any of these activities may stabilize or maintain the market price of the notes above independent market levels. The underwriters are
not required to engage in these activities, and may end any of these activities at any time.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We have agreed to indemnify the several underwriters
against certain liabilities, including liabilities under the Securities Act of 1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Prior to the offering, there have been no active
markets for the notes. The underwriters have advised us that certain of the underwriters presently intend to make markets in the notes
as permitted by applicable laws and regulations. Such underwriters are not obligated, however, to make the markets in the notes and any
such market making may be discontinued at any time at the discretion of such underwriters. Accordingly, no assurance can be given as to
the liquidity of, or trading markets for, the notes. We do not intend to apply for listing of the notes on any securities exchange.</P>


<!-- Field: Page; Sequence: 36 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The underwriters also may impose a penalty bid.
This occurs when a particular underwriter repays to the underwriters a portion of the underwriting discount received by it because the
representatives have repurchased notes sold by or for the account of such underwriter in stabilizing or short-covering transactions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The underwriters and their respective affiliates
are full service financial institutions engaged in various activities, which may include securities trading, commercial and investment
banking, financial advisory, investment management, investment research, principal investment, hedging, financing and brokerage activities.
Certain of the underwriters and their respective affiliates have, from time to time, performed, and may in the future perform, various
financial advisory, investment banking and commercial banking services for our company, for which they received or will receive customary
fees and expenses. In addition, affiliates of certain of the underwriters are lenders under our secured receivables credit facility and
our senior unsecured revolving credit facility. BNY Mellon Capital Markets, LLC, one of the underwriters, is an affiliate of the trustee.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">In the ordinary course of their various business
activities, the underwriters and their respective affiliates have made or held, and may in the future make or hold, a broad array of investments
including serving as counterparties to certain derivative and hedging arrangements, and may have actively traded, and, in the future may
actively trade, debt and equity securities (or related derivative securities), and financial instruments (including bank loans) for their
own account and for the accounts of their customers and may have in the past and at any time in the future hold long and short positions
in such securities and instruments. The underwriters and their respective affiliates may also communicate independent investment recommendations,
market color or trading ideas and/or publish or express independent research views in respect of such securities or instruments and may
at any time hold, or recommend to clients that they should acquire, long and/or short positions in such securities and instruments. Such
investment and securities activities may have involved, and in the future may involve, securities and instruments of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt 0.5in"><B>Conflicts of Interest</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">As described in &ldquo;Use of Proceeds&rdquo;
in this prospectus supplement, we expect to use the net proceeds from this offering for general corporate purposes, which may include
the redemption or repayment of indebtedness, including our 4.25% Senior Notes and any outstanding borrowings under our senior unsecured
revolving credit facility and our secured receivables credit facility. Certain of the underwriters (or their affiliates) may hold the
4.25% Senior Notes and would receive a portion of the proceeds from this offering if such notes were to be redeemed or repaid. In addition,
certain of the underwriters (or their affiliates) may be lenders under our senior unsecured revolving credit facility or our secured receivables
credit facility and would receive a portion of the proceeds from this offering if any outstanding borrowings under our credit facilities
were to be repaid. If any one underwriter, together with its affiliates, were to receive 5% or more of the net proceeds of this offering
by reason of the redemption or repayment, such underwriters would be deemed to have a &ldquo;conflict of interest&rdquo; within the meaning
of Rule 5121. Accordingly, this offering will be conducted in accordance with Rule 5121. No underwriter with a &ldquo;conflict of interest&rdquo;
under Rule 5121 will confirm sales to any account over which it exercises discretion without the specific written approval of the account
holder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Selling Restrictions</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Notice to Prospective Investors in the European Economic Area</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available
to any retail investor in the European Economic Area (&ldquo;EEA&rdquo;). For these purposes, a retail investor means a person who is
one (or more) of: (i) a retail client as defined in point (11) of Article 4(1) of Directive 2014/65/EU (as amended, &ldquo;MiFID II&rdquo;);
(ii) a customer within the meaning of Directive (EU) 2016/97 (as amended or superseded, the &ldquo;Insurance Distribution Directive&rdquo;),
where that customer would not qualify as a professional client as defined in point (10) of Article 4(1) of MiFID II; or (iii) not a qualified
investor as defined in Regulation (EU) 2017/1129 (as amended or superseded, the &ldquo;Prospectus Regulation&rdquo;). Consequently, no
key information document required by Regulation (EU) No 1286/2014 (as amended, the &ldquo;PRIIPs Regulation&rdquo;) for offering or selling
the notes or otherwise making them available to retail investors in the EEA has been prepared and therefore offering or selling the notes
or otherwise making them available to any retail investor in the EEA may be unlawful under the PRIIPs Regulation.</P>


<!-- Field: Page; Sequence: 37 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt"><B>Notice to Prospective Investors in the United Kingdom</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 1in">The notes are not intended to be offered, sold or otherwise made available to and should not be offered, sold or otherwise made available
to any retail investor in the United Kingdom (&ldquo;UK&rdquo;). For these purposes, a retail investor means a person who is one (or more)
of: (i) a retail client, as defined in point (8) of Article 2 of Regulation (EU) No 2017/565 as it forms part of domestic law by virtue
of the EUWA; (ii) a customer within the meaning of the provisions of the Financial Services and Markets Act 2000 (the &ldquo;FSMA&rdquo;)
and any rules or regulations made under the FSMA to implement the Insurance Distribution Directive, where that customer would not qualify
as a professional client, as defined in point (8) of Article 2(1) of Regulation (EU) No 600/2014 as it forms part of domestic law by virtue
of the EUWA; or (iii) not a qualified investor as defined in Article 2 of the Prospectus Regulation as it forms part of domestic law by
virtue of the EUWA (the &ldquo;UK Prospectus Regulation&rdquo;). Consequently, no key information document required by the PRIIPs Regulation
as it forms part of domestic law by virtue of the EUWA (the &ldquo;UK PRIIPs Regulation&rdquo;) for offering or selling the notes or otherwise
making them available to retail investors in the UK has been prepared and therefore offering or selling the notes or otherwise making
them available to any retail investor in the UK may be unlawful under the UK PRIIPs Regulation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt">Each underwriter has represented, warranted
and agreed that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(a) Financial promotion: it has only communicated or caused to be communicated and will only communicate or cause to be
communicated any invitation or inducement to engage in investment activity (within the meaning of section 21 of the FSMA) received by
it in connection with the issue or sale of any notes in circumstances in which section 21(1) of the FSMA does not apply to the issuer;
and</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">(b) General compliance: it has complied and will comply with all applicable provisions of the FSMA with respect to anything done by
it in relation to any notes in, from or otherwise involving the UK.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Notice to Prospective Investors in Hong Kong</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes may not be offered or sold by means
of any document other than (i) in circumstances which do not constitute an offer to the public within the meaning of the Companies Ordinance
(Cap.32, Laws of Hong Kong), or (ii) to &ldquo;professional investors&rdquo; within the meaning of the Securities and Futures Ordinance
(Cap.571, Laws of Hong Kong) and any rules made thereunder, or (iii) in other circumstances which do not result in the document being
a &ldquo;prospectus&rdquo; within the meaning of the Companies Ordinance (Cap.32, Laws of Hong Kong), and no advertisement, invitation
or document relating to the notes may be issued or may be in the possession of any person for the purpose of issue (in each case whether
in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be accessed or read by, the public in Hong Kong
(except if permitted to do so under the laws of Hong Kong) other than with respect to notes which are or are intended to be disposed of
only to persons outside Hong Kong or only to &ldquo;professional investors&rdquo; within the meaning of the Securities and Futures Ordinance
(Cap.571, Laws of Hong Kong) and any rules made thereunder.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Notice to Prospective Investors in Japan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes have not been and will not be registered
under the Financial Instruments and Exchange Law of Japan (the Financial Instruments and Exchange Law) and each underwriter has agreed
that it will not offer or sell any notes, directly or indirectly, in Japan or to, or for the benefit of, any resident of Japan (which
term as used herein means any person resident in Japan, including any corporation or other entity organized under the laws of Japan),
or to others for re-offering or resale, directly or indirectly, in Japan or to a resident of Japan, except pursuant to an exemption from
the registration requirements of, and otherwise in compliance with, the Financial Instruments and Exchange Law and any other applicable
laws, regulations and ministerial guidelines of Japan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Notice to Prospective Investors in Singapore</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">This prospectus has not been registered as a
prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with
the offer or sale, or invitation for subscription or purchase, of the notes may not be circulated or distributed, nor may the notes be
offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore
other than (i) to an institutional investor under Section 274 of the Securities and Futures Act, Chapter 289 of Singapore (the &ldquo;SFA&rdquo;),
(ii) to a relevant person, or any person pursuant to Section 275(1A), and in accordance with the conditions, specified in Section 275
of the SFA or (iii) otherwise pursuant to, and in accordance with the conditions of, any other applicable provision of the SFA. Solely
for the purposes of its obligations pursuant to Sections 309B(1)(a) and 309B(1)(c) of the SFA, the Company has determined, and hereby
notifies all relevant persons (as defined in Section 309A of the SFA) that the notes are &ldquo;prescribed capital markets products&rdquo;
(as defined in the Securities and Futures (Capital Markets Products) Regulations 2018) and Excluded Investment Products (as defined in
MAS Notice SFA 04-N12: Notice on the Sale of Investment Products and MAS Notice FAA-N16: Notice on Recommendations on Investment Products).</P>


<!-- Field: Page; Sequence: 38 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Where the notes are subscribed or purchased
under Section 275 by a relevant person which is: (a) a corporation (which is not an accredited investor) the sole business of which is
to hold investments and the entire share capital of which is owned by one or more individuals, each of whom is an accredited investor;
or (b) a trust (where the trustee is not an accredited investor) whose sole purpose is to hold investments and each beneficiary is an
accredited investor, shares, debentures and units of shares and debentures of that corporation or the beneficiaries&rsquo; rights and
interest in that trust shall not be transferable for 6 months after that corporation or that trust has acquired the notes under Section
275 except: (1) to an institutional investor under Section 274 of the SFA or to a relevant person, or any person pursuant to Section 275(1A),
and in accordance with the conditions, specified in Section 275 of the SFA; (2) where no consideration is given for the transfer; or (3)
by operation of law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt"><B>Notice to Prospective Investors in Canada</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The notes may be sold in Canada only to purchasers
purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument 45-106 Prospectus
Exemptions or subsection 73.3(1) of the Securities Act (Ontario), and are permitted clients, as defined in National Instrument 31-103
Registration Requirements, Exemptions and Ongoing Registrant Obligations. Any resale of the notes must be made in accordance with an exemption
from, or in a transaction not subject to, the prospectus requirements of applicable securities laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Securities legislation in certain provinces
or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus (including any amendment thereto)
contains a misrepresentation, <I>provided</I> that the remedies for rescission or damages are exercised by the purchaser within the time
limit prescribed by the securities legislation of the purchaser&rsquo;s province or territory. The purchaser should refer to any applicable
provisions of the securities legislation of the purchaser&rsquo;s province or territory for particulars of these rights or consult with
a legal advisor.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Pursuant to section 3A.3 of National Instrument
33-105 Underwriting Conflicts (NI 33-105), the underwriters are not required to comply with the disclosure requirements of NI 33-105 regarding
underwriter conflicts of interest in connection with this offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 39 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font-size: 10pt; width: 100%"><TR><TD STYLE="text-align: center; width: 100%">S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence -->&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="width: 100%"><TR><TD STYLE="text-align: center; width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><B><A NAME="a_009" TITLE="legalmatters"></A>LEGAL MATTERS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Certain legal matters in connection with the
notes offered hereby will be passed upon for us by Shearman &amp; Sterling LLP, New York, New York. Certain legal matters in connection
with the notes offered hereby will be passed upon for the underwriters by Fried, Frank, Harris, Shriver &amp; Jacobson LLP, New York,
New York.</P>

<P STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"> <B><A NAME="a_010" TITLE="experts_"></A>EXPERTS</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><B>&nbsp;</B></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The financial statements and management&rsquo;s
assessment of the effectiveness of internal control over financial reporting (which is included in the Report of Management on Internal
Control Over Financial Reporting) incorporated in this prospectus by reference to the Annual Report on Form 10-K for the year ended December
31, 2022 have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent registered public accounting
firm, given on the authority of said firm as experts in auditing and accounting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt 0.25in; text-align: center; text-indent: -0.25in"><B><A NAME="a_011" TITLE="moreinformation"></A>WHERE YOU CAN
FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We file annual, quarterly and current reports,
proxy statements and other information with the SEC. Our filings are also available to the public on the Internet, through the SEC at
http://www.sec.gov.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The SEC allows us to incorporate by reference
into this document the information we filed with it. This means that we can disclose important business, financial and other information
to you by referring you to other documents separately filed with the SEC. All information incorporated by reference is part of this document,
unless and until that information is updated and superseded by the information contained in this document or any information incorporated
later.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We incorporate by reference the documents listed
below (except for information furnished to the SEC that is not deemed to be &ldquo;filed&rdquo; for purposes of the Securities Exchange
Act of 1934, or the Exchange Act):</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Our Annual Report on Form 10-K for the fiscal year ended <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207923000018/dgx-20221231.htm">December 31, 2022</A>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Our Quarterly Reports on Form 10-Q for the quarters ended <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207923000093/dgx-20230331.htm">March 31, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207923000136/dgx-20230630.htm">June 30, 2023</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207923000157/dgx-20230930.htm">September 30, 2023</A>;</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>The information responsive to Part III of Form 10-K for the fiscal year ended December 31, 2022, provided in our Definitive Proxy
Statement on Schedule 14A, filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000093041323001199/c105212_def14a-ixbrl.htm">April 6, 2023</A>; and</TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Symbol">&#183;</FONT></TD><TD>Our Current Reports on Form 8-K, filed on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207923000006/dgx-20230202.htm">February 2, 2023</A> (current report filed under Item 8.01 only), <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207923000056/dgx-20230303.htm">March 7, 2023</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207923000104/dgx-20230517.htm">May 19, 2023</A>
and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207923000147/dgx-20230928.htm">September 29, 2023</A>.</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">The above list of documents that we are incorporating
by reference into this document amends and supersedes the list of documents included in the &ldquo;Where You Can Find More Information&rdquo;
section of the accompanying prospectus in its entirety.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">Our filings with the SEC, including our Annual
Report on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and amendments to those reports, are available free of
charge on our website as soon as reasonably practicable after they are filed with, or furnished to, the SEC. Our Internet website is located
at http://www.questdiagnostics.com. The contents of the website are not incorporated by reference into this prospectus supplement or the
accompanying prospectus. You also may request a copy of these filings, at no cost, by writing or telephoning our Investor Relations Department
at the following address:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 10pt; text-align: center">Quest Diagnostics Incorporated<BR>
500 Plaza Drive<BR>
Secaucus, NJ 07094<BR>
Attention: Investor Relations<BR>
(973) 520-2700</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-indent: 0.5in">We also incorporate by reference all future
filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act prior to the termination of the offering made
hereby. We will not, however, incorporate by reference in this prospectus supplement any documents or portions thereof furnished to the
SEC that are not deemed to be &ldquo;filed&rdquo; for purposes of the Exchange Act, including any information furnished pursuant to Item
2.02 or Item 7.01 of our Current Reports on Form 8-K after the date of this prospectus supplement unless, and except to the extent, specified
in such Current Reports on Form 8-K.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><BR></P>

<!-- Field: Page; Sequence: 40; Options: NewSection; Value: 39 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;S-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font-size: 10pt"><A HREF="#TableOfContents">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0">PROSPECTUS</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>QUEST DIAGNOSTICS INCORPORATED</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Debt Securities</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may offer and sell,
from time to time, in one or more offerings, the debt securities we describe in this prospectus.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We will provide the specific
terms of these debt securities in supplements or other offering material.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>We urge you to read
carefully this prospectus, the accompanying prospectus supplements and other offering material, which will describe the specific terms
of the securities offered, before you make your investment decision</B>.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may offer and sell these
debt securities for sale directly to purchasers or through underwriters, dealers or agents to be designated at a future date. See &#8220;Plan
of Distribution&#8221; and any prospectus supplement for a description of the manner in which we will offer and sell the debt securities
covered by this prospectus.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Investing in our debt
securities involves risks that are described in the &#8220;Risk Factors&#8221; section of our periodic reports filed with the Securities
and Exchange Commission or in the applicable prospectus supplement</B>.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The relevant prospectus
supplement will contain information, if applicable, as to whether the debt securities offered thereby will be listed for trading on any
securities exchange or other market.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy
or accuracy of this prospectus. Any representation to the contrary is a criminal offense</B>.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center">The date of this prospectus is July 25, 2022.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 41 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt; font-size: 10pt"><A HREF="#TableOfContents">Table of Contents</A></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="TableOfContents" TITLE="Table of Contents"></A>TABLE OF CONTENTS<FONT STYLE="font-family: Times New Roman, Times, Serif"><SUP></SUP></FONT></B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Page</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="width: 91%; padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a1">ABOUT THIS PROSPECTUS</A></FONT></TD>
    <TD STYLE="width: 9%; padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a2">WHERE YOU CAN FIND MORE INFORMATION</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">ii</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a3">CAUTIONARY STATEMENT FOR PURPOSES OF THE &#8220;SAFE HARBOR&#8221; PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">iii</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a4">PROSPECTUS SUMMARY</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">1</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a5">RISK FACTORS</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">2</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a6">USE OF PROCEEDS</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">3</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a7">SECURITIES WE MAY ISSUE</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">4</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a8">DESCRIPTION OF SENIOR DEBT SECURITIES</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">5</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a9">PLAN OF DISTRIBUTION</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">6</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: white">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a10">VALIDITY OF THE SECURITIES</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  <TR STYLE="vertical-align: top; background-color: #CCEEFF">
    <TD STYLE="padding: 1.75pt; line-height: 12.5pt"><FONT STYLE="font-size: 10pt; color: #0000EE"><A HREF="#a11">EXPERTS</A></FONT></TD>
    <TD STYLE="padding: 1.75pt; text-align: right; line-height: 12.5pt"><FONT STYLE="font-size: 10pt">7</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0">&nbsp;</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>








<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>






<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 42; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->i<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><A NAME="a1" TITLE="AboutThisProspectus"></A><B>ABOUT THIS PROSPECTUS</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The information contained
in this prospectus is not complete and may be changed. We have not authorized anyone to provide you with any information or to make any
representation not contained in or incorporated by reference into this prospectus or any prospectus supplement or included in any free
writing prospectus that we may file with the Securities and Exchange Commission (the &#8220;SEC&#8221;), in connection with any offering
of the debt securities described in this prospectus. We do not take any responsibility for, and can provide no assurances as to, the reliability
of any information that others may provide you. We are not making an offer of any securities in any jurisdiction where the offer is not
permitted. You should not assume that the information in this prospectus, any prospectus supplement or any document incorporated by reference
is accurate as of any date other than the date of the document in which such information is contained or such other date referred to in
such document, regardless of the time of any sale or issuance of a security.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus is part
of a registration statement that we filed with the SEC using a &#8220;shelf&#8221; registration process. This prospectus provides you
with a limited description of the securities we may offer. Each time we sell or issue securities, we will provide a prospectus supplement
and, if applicable, a pricing supplement, that will contain specific information about the terms of that specific offering of securities
and the specific manner in which they may be offered. The prospectus supplement and any applicable pricing supplement may also add to,
update or change any of the information contained in this prospectus. The prospectus supplement and any applicable pricing supplement
may also contain information about any material U.S. federal income tax considerations relating to the securities described in the prospectus
supplement. You should read both this prospectus, the applicable prospectus supplement and any applicable pricing supplement, together
with the additional information, which is incorporated by reference in this prospectus, described under &#8220;Where You Can Find More
Information.&#8221; You should read the entire prospectus and the applicable prospectus supplement, including the information incorporated
by reference, before making an investment decision.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As used in this prospectus,
the terms &#8220;Quest Diagnostics,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; refer to Quest Diagnostics Incorporated
and its consolidated subsidiaries, unless the context clearly indicates otherwise.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus contains
summaries of certain provisions contained in some of the documents described herein, but reference is made to the actual document for
complete information. All of the summaries are qualified in their entirety by the actual documents. Copies of some of the documents referred
to herein have been filed or will be filed or incorporated by reference as exhibits to the registration statement of which this prospectus
is a part, and you may obtain copies of those documents as described below under &#8220;Where You Can Find More Information.&#8221;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The registration statement
that contains this prospectus (including the exhibits to the registration statement) contains additional information about us and the
securities offered under this prospectus. That registration statement can be read at the SEC website (www.sec.gov).</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a2" TITLE="Where Your Can Find"></A>WHERE YOU CAN FIND MORE INFORMATION</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We file annual, quarterly
and current reports, proxy statements and other information with the SEC. Our filings are available to the public on the Internet, through
a database maintained by the SEC at http://www.sec.gov.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The SEC allows us to incorporate
by reference into this document the information we filed with the SEC. This means that we can disclose important business, financial and
other information to you by referring you to other documents separately filed with the SEC. All information incorporated by reference
is part of this document, unless and until that information is updated and superseded by the information contained in this document, any
prospectus supplement or in any document that we file with the SEC after the date hereof that is incorporated herein.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 43 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->ii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We incorporate by reference
the following documents filed with the SEC:</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt/12.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">1.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our
current reports on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000094787122000132/ss773888_8k.htm">Form 8-K, filed
with the SEC on February 3, 2022</A> (film no. 22586518) (as amended by our current reports on Form
8-K/A filed with the SEC on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/0001022079/000102207922000045/dgx-20220203.htm">March 1, 2022</A> and on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000094787122000737/ss1131121_8ka.htm">July 1, 2022</A>), <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207922000008/dgx-20220203.htm">February
3, 2022 (current report filed under Item 8.01 only) (film no. 22586494)</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207922000046/dgx-20220224.htm">March 1, 2022</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207922000048/dgx-20220224.htm">March 2, 2022</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207922000079/dgx-20220518.htm">May 20, 2022 (film no. 22945254)</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000094787122000627/ss1016027_8k.htm">May
20, 2022 (film no. 22948002)</A>, <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207922000100/dgx-20220520.htm">May 25, 2022</A> and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207922000107/dgx-20220608.htm">June 14, 2022 (current report filed under Item 5.02 only)</A>;</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt/12.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">2.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207922000027/dgx-20211231.htm">annual report on Form 10-K for the fiscal year ended December 31, 2021</A>
(the &#8220;2021 Form 10-K&#8221;);</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt/12.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">3.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Portions of our <A HREF="https://www.sec.gov/Archives/edgar/data/1022079/000094787122000463/ss916215_def14a.htm">proxy statement on Schedule 14A</A>, filed with the SEC on April
19, 2022, that are incorporated by reference into Part III of our Form 10-K for the fiscal year ended December 31, 2021; and</FONT></TD></TR></TABLE>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 12pt/12.5pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.5in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-size: 10pt">4.</FONT></TD><TD STYLE="text-align: justify"><FONT STYLE="font-size: 10pt">Our quarterly reports on <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207922000074/dgx-20220331.htm">Form 10-Q for the quarter ended March 31, 2022</A>
and <A HREF="https://www.sec.gov/ix?doc=/Archives/edgar/data/1022079/000102207922000123/dgx-20220630.htm">the quarter ended June 30, 2022</A>.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We also incorporate by
reference all future filings we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as
amended (the &#8220;Exchange Act&#8221;), prior to the completion of the offering of the particular securities covered by a prospectus
supplement or term sheet.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Our filings with the SEC,
including our annual report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports,
are available free of charge on our website as soon as reasonably practicable after they are filed with, or furnished to, the SEC.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">You also may request a
copy of these filings, at no cost, by writing or telephoning our Investor Relations Department at the following address:</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center">Quest Diagnostics Incorporated<BR>
500 Plaza Drive<BR>
Secaucus, New Jersey 07094<BR>
Attention: Investor Relations<BR>
(973) 520-2700</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">These filings may also
be obtained from our internet website located at http://www.questdiagnostics.com. The contents of the website are not incorporated by
reference into this prospectus.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a3" TITLE="Cautionary Statement"></A>CAUTIONARY STATEMENT FOR PURPOSES OF THE
&#8220;SAFE HARBOR&#8221; PROVISIONS OF THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Some statements and disclosures
in this prospectus, any accompanying prospectus supplement or other offering material and the documents incorporated herein or therein
by reference are forward-looking statements. Forward-looking statements include all statements that do not relate solely to historical
or current facts and can be identified by the use of words such as &#8220;may,&#8221; &#8220;believe,&#8221; &#8220;will,&#8221; &#8220;expect,&#8221;
&#8220;project,&#8221; &#8220;estimate,&#8221; &#8220;anticipate,&#8221; &#8220;plan&#8221; or &#8220;continue.&#8221; These forward-looking
statements are based on our current plans and expectations and are subject to a number of risks and uncertainties that could cause our
plans and expectations, including actual results, to differ materially from the forward-looking statements.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 44 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iii<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The Private Securities
Litigation Reform Act of 1995, or the Litigation Reform Act, provides a &#8220;safe harbor&#8221; for forward-looking statements to encourage
companies to provide prospective information about their companies without fear of litigation. We would like to take advantage of the
&#8220;safe harbor&#8221; provisions of the Litigation Reform Act in connection with the forward-looking statements included or incorporated
by reference in this document. Investors are cautioned not to unduly rely on such forward-looking statements when evaluating the information
presented or incorporated by reference in this document. The following important factors could cause our actual financial results to differ
materially from those projected, forecasted or estimated by us in forward-looking statements:</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(a)&nbsp;&nbsp;&nbsp;&nbsp;Heightened
competition from commercial clinical testing companies, Independent Delivery Networks (including hospitals and hospital health systems)
(&#8220;IDNs&#8221;), physicians and others.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(b)&nbsp;&nbsp;&nbsp;&nbsp;Increased
pricing pressure from customers, including payers and patients, and changing relationships with customers, payers, suppliers and strategic
partners.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(c)&nbsp;&nbsp;&nbsp;&nbsp;A decline
in economic conditions.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(d)&nbsp;&nbsp;&nbsp;&nbsp;Impact of
changes in payment mix, including increased patient financial responsibility and any shift from fee-for-service to discounted, capitated
or bundled fee arrangements.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(e)&nbsp;&nbsp;&nbsp;&nbsp;Adverse
actions by government or other third-party payers, including healthcare reform that focuses on reducing healthcare costs but does not
recognize the value and importance to healthcare of clinical testing or innovative solutions, unilateral reduction of fee schedules payable
to us, unilateral recoupment of amounts allegedly owed and competitive bidding.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(f)&nbsp;&nbsp;&nbsp;&nbsp;The impact
upon our testing volume and collected revenue or general or administrative expenses resulting from compliance with policies and requirements
imposed by Medicare, Medicaid and other third-party payers. These include:</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-indent: -0.3in">(1)&nbsp;&nbsp;&nbsp;&nbsp;the requirements
of government and other payers to provide diagnosis codes and other information for many tests;</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-indent: -0.3in">(2)&nbsp;&nbsp;&nbsp;&nbsp;inability
to obtain from patients a valid advance consent form for tests that cannot be billed without prior receipt of the form;</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-indent: -0.3in">(3)&nbsp;&nbsp;&nbsp;&nbsp;the impact
of additional or expanded limited coverage policies and limits on the allowable number of test units or ordering frequency of same; and</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-indent: -0.3in">(4)&nbsp;&nbsp;&nbsp;&nbsp;the impact
of increased prior authorization programs.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(g)&nbsp;&nbsp;&nbsp;&nbsp;Adverse
results from pending or future government investigations, lawsuits or private actions. These include, in particular, monetary damages,
loss or suspension of licenses, and/or suspension or exclusion from the Medicare and Medicaid programs and/or criminal penalties.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(h)&nbsp;&nbsp;&nbsp;&nbsp;Failure
to efficiently integrate acquired businesses and to manage the costs related to any such integration, or to retain key technical, professional
or management personnel.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(i)&nbsp;&nbsp;&nbsp;&nbsp;Denial,
suspension or revocation of Clinical Laboratory Improvement Act (&#8220;CLIA&#8221;) certification or other licenses for any of our clinical
laboratories under the CLIA standards, revocation or suspension of the right to bill the Medicare and Medicaid programs or other adverse
regulatory actions by federal, state and local agencies.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(j)&nbsp;&nbsp;&nbsp;&nbsp;Changes
in and complexity of federal, state or local laws or regulations, including changes that result in new or increased federal or state regulation
of commercial clinical laboratories, tests developed by commercial clinical laboratories or other products or services that we offer or
activities in which we are engaged, including regulation by the U.S. Food and Drug Administration.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(k)&nbsp;&nbsp;&nbsp;&nbsp;Inability
to achieve expected benefits from our acquisitions of other businesses.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in"></P>

<!-- Field: Page; Sequence: 45 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->iv<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(l)&nbsp;&nbsp;&nbsp;&nbsp; Inability
to achieve additional benefits from our business performance tools and efficiency initiatives.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(m)&nbsp;&nbsp;&nbsp;Adverse publicity
and news coverage about the diagnostic information services industry or us.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(n)&nbsp;&nbsp;&nbsp;&nbsp;Failure
of the Company to maintain, defend and secure its financial, accounting, technology, customer data and other operational systems from
cyberattacks, IT system outages, telecommunications failures, malicious human acts and failure of the systems of third parties upon which
the Company relies.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(o)&nbsp;&nbsp;&nbsp;&nbsp;Development
of technologies that substantially alter the practice of clinical testing, including technology changes that lead to the development of
more convenient or cost-effective testing, or testing to be performed outside of a commercial clinical laboratory, such as (1) point-of-care
testing that can be performed by physicians in their offices, (2) advanced testing that can be performed by IDNs in their own laboratories
or (3) home testing that can be carried out without requiring the services of clinical laboratories.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(p)&nbsp;&nbsp;&nbsp;&nbsp;Negative
developments regarding intellectual property and other property rights that could prevent, limit or interfere with our ability to develop,
perform or sell our tests or operate our business. These include:</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-indent: -0.3in">(1)&nbsp;&nbsp;&nbsp;&nbsp;issuance
of patents or other property rights to our competitors or others; and</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.6in; text-indent: -0.3in">(2)&nbsp;&nbsp;&nbsp;&nbsp;inability
to obtain or maintain adequate patent or other proprietary rights for our products and services or to successfully enforce our proprietary
rights.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(q)&nbsp;&nbsp;&nbsp;&nbsp;Development
of tests by our competitors or others which we may not be able to license, or usage (or theft) of our technology or similar technologies
or our trade secrets or other intellectual property by competitors, any of which could negatively affect our competitive position.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(r)&nbsp;&nbsp;&nbsp;&nbsp; Regulatory
delay or inability to commercialize newly developed or licensed tests or technologies or to obtain appropriate reimbursements for such
tests.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(s)&nbsp;&nbsp;&nbsp;&nbsp;The complexity
of billing and revenue recognition for clinical laboratory testing.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(t)&nbsp;&nbsp;&nbsp; &nbsp;Increases
in interest rates and negative changes in our credit ratings from Standard &amp; Poor's, Moody's Investor Services or Fitch Ratings causing
an unfavorable impact on our cost of or access to capital.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(u)&nbsp;&nbsp;&nbsp;&nbsp;Inability
to hire or retain qualified employees, including key senior management personnel.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(v)&nbsp;&nbsp;&nbsp;&nbsp;Terrorist
and other criminal activities, hurricanes, earthquakes or other natural disasters, and public health emergencies and health pandemics,
which could affect our customers or suppliers, transportation or systems, or our facilities, and for which insurance may not adequately
reimburse us.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(w)&nbsp;&nbsp;&nbsp;Difficulties and
uncertainties in the discovery, development, regulatory environment and/or marketing of new services or solutions or new uses of existing
tests.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">(x)</TD><TD><FONT STYLE="background-color: white">Failure to adapt to changes in the healthcare system (including the medical laboratory testing
market) and healthcare delivery, including those stemming from the Protecting Access to Medicare Act, trends in utilization of the healthcare
system and increased patient financial responsibility for services.</FONT></TD></TR></TABLE>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(y) &nbsp;&nbsp;&nbsp;Results
and consequences of governmental inquiries.</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0"></TD><TD STYLE="width: 0.3in">(z)</TD><TD>Difficulty in implementing, or lack of success with, our strategic plan.</TD></TR></TABLE>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(aa) &nbsp;The impact of healthcare data
analysis on our industry and the ability of our Company to adapt to that impact.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(bb) &nbsp;Failure to adequately operationalize
appropriate controls around use of our data, including risk of non- compliance with privacy law requirements.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(cc) &nbsp;The COVID-19 pandemic.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">(dd) &nbsp;Other risks outlined in our periodic
filings with the SEC.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0">Our forward-looking statements are expressly qualified in their entirety
by this cautionary statement. We undertake no obligation to update our forward-looking statements to reflect new information or events
or circumstances arising after the date such forward-looking statements were made.</P>

<P STYLE="font: 10pt/125% Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-indent: -0.3in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"></P>

<!-- Field: Page; Sequence: 46 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;<!-- Field: Sequence; Type: LowerRoman; Name: PageNo -->v<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B><A NAME="a4" TITLE="Prospectus Summary"></A>PROSPECTUS SUMMARY</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><I>This summary highlights some of the information
incorporated by reference into this prospectus. Because this is only a summary, it does not contain all of the information that may be
important to you. You should carefully read this prospectus, the applicable prospectus supplement, and any other offering material including
the documents incorporated by reference, which are described under &#8220;Where You Can Find More Information.&#8221; You should also
carefully consider, among other things, the matters discussed in the section entitled &#8220;Risk Factors.&#8221;<BR>
<BR>
</I></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0"><B>The Company<BR>
<BR>
</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Quest Diagnostics empowers people to take action
to improve health outcomes. We use our extensive database of clinical lab results to derive diagnostic insights that reveal new avenues
to identify and treat disease, inspire healthy behaviors and improve healthcare management. Our diagnostic information services business
provides information and insights based on the industry-leading menu of routine, non-routine and advanced clinical testing and anatomic
pathology testing, and other diagnostic information services. We provide services to a broad range of customers, including patients, clinicians,
hospitals, independent delivery networks, health plans, employers, accountable care organizations, and direct contract entities. We offer
the broadest access in the United States to diagnostic information services through our nationwide network of laboratories, patient service
centers and phlebotomists in physician offices and our connectivity resources, including call centers and mobile paramedics, nurses and
other health and wellness professionals. We are the world's leading provider of diagnostic information services. We provide interpretive
consultation with one of the largest medical and scientific staffs in the industry. Our diagnostics information services business makes
up greater than 95% of our consolidated net revenues. During 2021, we processed approximately 218 million test requisitions through our
extensive laboratory network.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">In our Diagnostic Solutions businesses, which
represent the balance of our consolidated net revenues, we offer a variety of solutions for life insurers and healthcare organizations
and clinicians. We are the leading provider of risk assessment services for the life insurance industry. In addition, we offer healthcare
organizations and clinicians robust information technology solutions.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The patients we serve comprise approximately
one-third of the adult population of the United States annually, and approximately one-half of the adult population in the United States
over a three-year period. We estimate that annually we serve approximately half of the physicians and half of the hospitals in the United
States.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Quest Diagnostics was incorporated in Delaware
in 1990; its predecessor companies date back to 1967. We conduct business through our headquarters in Secaucus, New Jersey, and our laboratories,
patient service centers, offices and other facilities around the United States and in selected locations outside the United States.&nbsp;During
2021, we generated net revenues of $10.8 billion, including $8.0 billion of base business revenues (which excludes COVID-19 molecular
and antibody testing) and $2.8 billion of COVID-19 testing revenues.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-indent: 0.5in">Our principal executive offices are located
at 500 Plaza Drive, Secaucus, New Jersey 07094, telephone number: (973) 520-2700.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 47; Options: NewSection -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a5" TITLE="Risk Factors"></A>RISK FACTORS</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">Our business is subject to significant risks.
You should carefully consider the risks and uncertainties set forth in Part I, Item 1A. under the heading &#8220;Risk Factors&#8221; included
in our 2021 Form 10-K and in &#8220;Item 1A. Risk Factors&#8221; in any quarterly report on Form 10-Q, which are incorporated by reference
in this prospectus. Additional risk factors that you should carefully consider will also be included in a prospectus supplement relating
to an offering of our securities as well as the other documents filed with the SEC that are incorporated by reference herein or therein.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The risks and uncertainties described in any
accompanying prospectus supplement as well as the documents incorporated by reference herein or therein are not the only ones facing us.
Additional risks and uncertainties that we do not presently know about or that we currently believe are not material may also adversely
affect our business. If any of the risks and uncertainties described in this prospectus, any accompanying prospectus supplement or the
documents incorporated by reference herein or therein actually occur, our business, financial condition, results of operations and prospects
could be adversely affected in a material way. The occurrence of any of these risks may cause you to lose all or part of your investment
in the offered securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 48 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B><A NAME="a6" TITLE="Use of Proceeds"></A>USE OF PROCEEDS</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Except as may be described
otherwise in a prospectus supplement or other offering material, we will add the net proceeds from the sale of the securities under this
prospectus to our general funds and will use them for general corporate purposes, which may include, among other things, funding acquisitions,
capital expenditures, or reducing or refinancing indebtedness.</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<!-- Field: Page; Sequence: 49 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B><A NAME="a7" TITLE="Securities We May Issue"></A>SECURITIES WE MAY ISSUE</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0"><B>Overview</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus is part
of a registration statement that we filed with the SEC utilizing a &#8220;shelf&#8221; registration process. Under this shelf process,
we may sell our debt securities in one or more offerings.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The terms of the debt securities
will be determined at the time of offering.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0"><B>Prospectus Supplement or Pricing Supplement</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">This prospectus provides
you with a general description of the debt securities we may offer. Each time we sell debt securities, we will provide a prospectus supplement
or pricing supplement that will contain specific information about the terms of that offering. The prospectus supplement or pricing supplement
may also add to or change information contained in this prospectus. If so, the prospectus supplement or pricing supplement should be read
as superseding this prospectus. You should read both this prospectus and any prospectus supplement or pricing supplement together with
additional information described under the heading &#8220;Where You Can Find More Information.&#8221;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The prospectus supplement
or pricing supplement to be provided with this prospectus will describe the terms of any debt securities that we offer and any initial
offering price to the public in that offering, the purchase price and net proceeds that we will receive and the other specific terms related
to our offering of the debt securities. For more details on the terms of the debt securities, you should read the exhibits filed with
or incorporated by reference in our registration statement, of which this prospectus is a part.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 50 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B><A NAME="a8" TITLE="Description of Senior Notes"></A>DESCRIPTION OF SENIOR DEBT SECURITIES<BR>
<BR>
</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may issue senior debt
securities from time to time in one or more distinct series.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As required by U.S. federal
law for all bonds and notes of companies that are publicly offered, the senior debt securities will be governed by a document called an
&#8220;indenture.&#8221; An indenture is a contract between us and a financial institution, in this case, The Bank of New York Mellon
formerly known as The Bank of New York, acting as trustee on your behalf, or other trustee we may select. The indenture will be subject
to and governed by the Trust Indenture Act of 1939.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We have filed the indenture
as an exhibit to our Securities Act of 1933, as amended (&#8220;Securities Act&#8221;), filings and Exchange Act reports that we have
filed with the SEC. See &#8220;Where You Can Find More Information&#8221; for information on how to obtain a copy of the indenture.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in">The senior debt securities will be issued under an
indenture dated as of June 27, 2001 as supplemented by a first supplemental indenture, dated as of June 27, 2001, each among Quest Diagnostics,
as issuer, the Initial Subsidiary Guarantors (as defined therein), as guarantors, and The Bank of New York, as trustee, as further supplemented
by a second supplemental indenture, dated as of November 26, 2001, among Quest Diagnostics, the Subsidiary Guarantors (as defined therein)
and The Bank of New York, as further supplemented by a third supplemental indenture, dated as of April 4, 2002, among Quest Diagnostics,
the Additional Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented by a fourth supplemental indenture,
dated as of March 19, 2003, among Quest Diagnostics, the Additional Subsidiary Guarantor (as defined therein) and The Bank of New York,
as further supplemented by a fifth supplemental indenture, dated as of April 16, 2004, among Quest Diagnostics, the Additional Subsidiary
Guarantor (as defined therein) and The Bank of New York, as further supplemented by a sixth supplemental indenture, dated as of October
31, 2005, among Quest Diagnostics, the Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented by
a seventh supplemental indenture, dated as of November 21, 2005, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined
therein) and The Bank of New York, as further supplemented by an eighth supplemental indenture, dated as of July 31, 2006, among Quest
Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented by the ninth
supplemental indenture dated, September 30, 2006, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and
The Bank of New York, as further supplemented by the tenth supplemental indenture, dated June 22, 2007, among Quest Diagnostics, the Subsidiary
Guarantors (as defined therein) and The Bank of New York, as further supplemented by the eleventh supplemental indenture, dated June 22,
2007, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined therein) and The Bank of New York, as further supplemented
by the twelfth supplemental indenture, dated June 25, 2007, among Quest Diagnostics, the Additional Subsidiary Guarantors (as defined
therein) and The Bank of New York, as further supplemented by the thirteenth supplemental indenture, dated November 17, 2009, among Quest
Diagnostics, the Subsidiary Guarantors (as defined therein) and The Bank of New York Mellon, as further supplemented by the fourteenth
supplemental indenture, dated March 24, 2011, among Quest Diagnostics, the Subsidiary Guarantors (as defined therein) and The Bank of
New York Mellon, as further supplemented by the fifteenth supplemental indenture, dated November 30, 2011, among Quest Diagnostics, the
Additional Subsidiary Guarantors (as defined therein) and The Bank of New York Mellon, as further supplemented by the sixteenth supplemental
indenture, dated March 17, 2014, between Quest Diagnostics and The Bank of New York Mellon, as further supplemented by the seventeenth
supplemental indenture, dated March 10, 2015, between Quest Diagnostics and The Bank of New York Mellon, as further supplemented by the
eighteenth supplemental indenture, dated as of May 26, 2016, between Quest Diagnostics and The Bank of New York Mellon, as further supplemented
by the nineteenth supplemental indenture, dated as of March 12, 2019, between Quest Diagnostics and The Bank of New York Mellon, as further
supplemented by the twentieth supplemental indenture, dated as of December 16, 2019, between Quest Diagnostics and The Bank of New York
Mellon, and as further supplemented by the twenty-first supplemental indenture, dated as of May 13, 2020, between Quest Diagnostics and
The Bank of New York Mellon (collectively, as so supplemented, the &#8220;Indenture&#8221;). The Indenture for the senior debt securities
may also be modified by future supplemental indentures. The terms of the senior debt securities include those stated in the Indenture
and those made part of the Indenture by reference to the Trust Indenture Act of 1939. A copy of the Indenture is available for inspection
at the office of the trustee.</P>



<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"></P>

<!-- Field: Page; Sequence: 51 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B><A NAME="a9" TITLE="Plan of Distribution"></A>PLAN OF DISTRIBUTION</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may sell the debt securities
to or through agents, dealers or underwriters or directly to one or more purchasers.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0"><B>By Agents</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may use agents to sell
the debt securities. Unless otherwise stated in a prospectus supplement or other offering material, the agents will agree to use their
reasonable best efforts to solicit purchases for the period of their appointment.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0"><B>By Underwriters or Dealers</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may sell the debt securities
to underwriters. The underwriters may resell the debt securities in one or more transactions, including negotiated transactions, at a
fixed public offering price or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the debt
securities will be subject to certain conditions. Each underwriter will be obligated to purchase all the debt securities allocated to
it under the underwriting agreement. The underwriters may change any initial public offering price and any discounts or concessions they
give to dealers.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">A prospectus supplement
and/or any additional offering material will state the name of any underwriter and the amount of compensation, underwriting discounts,
commissions, or concessions paid or allowed.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0"><B>Direct Sales</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may sell debt securities
directly to investors. In this case, no underwriters, dealers or agents would be involved.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">As one of the means of
direct issuance of debt securities, we may utilize the services of any available electronic auction system to conduct an electronic &#8220;Dutch
auction&#8221; of the offered securities among potential purchasers who are eligible to participate in the auction of those offered debt
securities, if so described in the prospectus supplement or pricing supplement.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0"><B>General Information</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">We may have agreements
with the underwriters, dealers and agents to indemnify them against certain civil liabilities, including liabilities under the Securities
Act, or to contribute to payments they may be required to make.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">Underwriters, dealers and
agents may engage in transactions with, or perform services for, us or our subsidiaries in the ordinary course of their business.</P>



<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><B></B></P>

<!-- Field: Page; Sequence: 52 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"><A NAME="a10" TITLE="Validity of the Securities"></A><B>VALIDITY OF THE SECURITIES<BR>
<BR>
</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The validity of any securities
issued hereunder will be passed upon for us by Shearman &amp; Sterling LLP, New York, New York.</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B><A NAME="a11" TITLE="Experts"></A>EXPERTS<BR>
<BR>
</B></P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in">The financial statements
and management&#8217;s assessment of the effectiveness of internal control over financial reporting (which is included in the Report of
Management on Internal Control over Financial Reporting) incorporated in this prospectus by reference to the Annual Report on Form 10-K
for the year ended December 31, 2021, have been so incorporated in reliance on the report of PricewaterhouseCoopers LLP, an independent
registered public accounting firm, given on the authority of said firm as experts in auditing and accounting.</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Page; Sequence: 53 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 2pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence -->&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="font-size: 10pt; margin: 0pt"><A HREF="#TableOfContents">Table of Contents</A>&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 0pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid; border-bottom: Black 1pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/12.5pt Times New Roman, Times, Serif; margin: 10pt 0 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 18pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">$750,000,000</P>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: center"><IMG SRC="image_002.jpg" ALT="Description: C:\Users\dy23967\Desktop\Quest-logo[2].jpg" STYLE="height: 115px; width: 241px"></P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center">Quest Diagnostics Incorporated</P>

<P STYLE="font: 14pt Times New Roman, Times, Serif; margin: 0 0 24pt; text-align: center">6.400% Senior
Notes due 2033</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>PROSPECTUS SUPPLEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Goldman Sachs &amp; Co. LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Mizuho</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Morgan Stanley</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>J.P. Morgan</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Wells Fargo Securities&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Credit Agricole CIB</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>MUFG</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>PNC Capital Markets LLC</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>Fifth Third Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>KeyBanc Capital Markets</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>BofA Securities</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center"><B>BNY Mellon Capital Markets,
LLC&nbsp;</B></P>

<P STYLE="font: 9pt Times New Roman, Times, Serif; margin: 0 0 12pt; text-align: center; text-indent: 0in"><B>October 30, 2023</B></P>

<P STYLE="font: 11pt/107% Calibri, Helvetica, Sans-Serif; margin: 0 0 8pt">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 12pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1pt solid; border-bottom: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-FILING FEES
<SEQUENCE>2
<FILENAME>ss2656398_ex107.htm
<DESCRIPTION>CALCULATION OF FILING FEE TABLES
<TEXT>
<HTML>
<HEAD>
<TITLE></TITLE>
</HEAD>
<BODY>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: right"><B>Exhibit 107</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><B>Calculation of Filing Fee Tables</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>424(b)(2)</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Form Type)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Quest Diagnostics Incorporated</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">(Exact Name of Registrant as Specified in its Charter)</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Table 1: Newly Registered and Carry Forward Securities</B></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 7%; border: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 6%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; border-right: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Security</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Type</B></P></TD>
    <TD STYLE="white-space: nowrap; width: 7%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; border-right: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Security</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Class</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Title</B></P></TD>
    <TD STYLE="white-space: nowrap; width: 8%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; border-right: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fee</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Calculation</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>or Carry</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Forward</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Rule</B></P></TD>
    <TD STYLE="white-space: nowrap; width: 15%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; border-right: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registered</B></P></TD>
    <TD STYLE="white-space: nowrap; width: 7%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; border-right: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Proposed</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Maximum</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Offering</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Price</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Per</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Unit</B></P></TD>
    <TD STYLE="white-space: nowrap; width: 9%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; border-right: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Maximum</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Aggregate</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Offering</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Price</B></P></TD>
    <TD STYLE="white-space: nowrap; width: 7%; border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Fee Rate</B></TD>
    <TD STYLE="white-space: nowrap; width: 8%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; border-right: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Amount of</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Registration</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Fee (1)</B></P></TD>
    <TD STYLE="padding-right: 3pt; white-space: nowrap; width: 6%; border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; padding-left: 3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Carry</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Forward</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Form</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Type</B></P></TD>
    <TD STYLE="padding-right: 3pt; white-space: nowrap; width: 6%; border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; padding-left: 3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Carry</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Forward</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>File</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Number</B></P></TD>
    <TD STYLE="padding-right: 3pt; white-space: nowrap; width: 6%; border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; padding-left: 3pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Carry</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Forward</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Initial</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>effective</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>date</B></P></TD>
    <TD STYLE="white-space: nowrap; width: 8%; border-top: black 1.5pt solid; border-bottom: black 1.5pt solid; border-right: black 1.5pt solid">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Filing Fee</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Previously</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Paid In</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Connection</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>with</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Unsold</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Securities</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>to</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>be</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Carried</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><B>Forward</B></P></TD></TR>
  <TR>
    <TD COLSPAN="13" STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Newly Registered Securities</B></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Fees to Be Paid</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">Debt</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">6.400% Notes due 2033</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">457(r)</TD>
    <TD STYLE="padding-right: 3pt; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3pt">$750,000,000</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">99.947%</TD>
    <TD STYLE="padding-right: 3pt; white-space: nowrap; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; padding-left: 3pt">&nbsp;$749,602,500</TD>
    <TD STYLE="padding-right: 3pt; white-space: nowrap; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; padding-left: 3pt">0.0001476</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">$110,641.33</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR>
    <TD COLSPAN="13" STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><B>Carry Forward Securities</B></TD></TR>
  <TR>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Carry Forward Securities</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-right: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-right: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-top: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Total Offering Amounts</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">$749,602,500</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">$110,641.33</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; border-right: black 1.5pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Total Fees Previously Paid</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; border-right: black 1.5pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Total Fee Offsets</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-bottom: black 1.5pt solid; border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  <TR>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; border-left: black 1.5pt solid">&nbsp;</TD>
    <TD COLSPAN="4" STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif">Net Fee Due</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center">$110,641.33</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD>
    <TD STYLE="border-right: black 1.5pt solid; border-bottom: black 1.5pt solid">&nbsp;</TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">(1) Calculated in accordance with Rule 457(r) of the Securities Act of
1933, as amended.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0">&nbsp;</P>


<!-- Field: Rule-Page --><DIV STYLE="margin-top: 3pt; margin-bottom: 3pt; width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 2pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->



</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image_001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_001.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "0 2T# 2(  A$! Q$!_\0
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<H **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>image_002.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_002.jpg
M_]C_X  02D9)1@ ! 0$ > !X  #_VP!#  H'!PD'!@H)" D+"PH,#QD0#PX.
M#QX6%Q(9)" F)2,@(R(H+3DP*"HV*R(C,D0R-CL]0$! )C!&2T4^2CD_0#W_
MVP!# 0L+"P\-#QT0$!T]*2,I/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3T]
M/3T]/3T]/3T]/3T]/3T]/3T]/3T]/3W_P  1" "0 2T# 2(  A$! Q$!_\0
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M1Q2(WFH!(4[A=V<?D:H>%/&=IH>C/:W44KL)&=#&,ALUZ455@58 J>H-9?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
AHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
